https://bordet.makemeweb.dev/en/efficacy-adjuvant-trastuzumab-patients-human-epidermal-growth-factor-receptor-2-positive-early 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/efficacy-adjuvant-trastuzumab-patients-human-epidermal-growth-factor-receptor-2-positive-early 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/efficacy-adjuvant-trastuzumab-patients-human-epidermal-growth-factor-receptor-2-positive-early 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/identification-clinical-parameters-predictive-one-year-survival-using-two-geriatric-tools 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/identification-clinical-parameters-predictive-one-year-survival-using-two-geriatric-tools 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/identification-clinical-parameters-predictive-one-year-survival-using-two-geriatric-tools 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/implementation-geriatric-assessment-based-recommendations-older-patients-cancer-multicentre 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/implementation-geriatric-assessment-based-recommendations-older-patients-cancer-multicentre 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/implementation-geriatric-assessment-based-recommendations-older-patients-cancer-multicentre 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/snps-mir-155-binding-sites-tyrp1-explain-discrepancy-between-mrna-and-protein-and-refine-tyrp1 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/snps-mir-155-binding-sites-tyrp1-explain-discrepancy-between-mrna-and-protein-and-refine-tyrp1 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/snps-mir-155-binding-sites-tyrp1-explain-discrepancy-between-mrna-and-protein-and-refine-tyrp1 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/first-human-phase-i-and-pharmacokinetic-study-cp-4126-co-101-nucleoside-analogue-patients-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/first-human-phase-i-and-pharmacokinetic-study-cp-4126-co-101-nucleoside-analogue-patients-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/first-human-phase-i-and-pharmacokinetic-study-cp-4126-co-101-nucleoside-analogue-patients-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/erdheim-chester-disease-case-report 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/erdheim-chester-disease-case-report 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/erdheim-chester-disease-case-report 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/virulence-factors-streptococcus-pneumoniae-comparison-between-african-and-french-invasive-isolates 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/virulence-factors-streptococcus-pneumoniae-comparison-between-african-and-french-invasive-isolates 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/virulence-factors-streptococcus-pneumoniae-comparison-between-african-and-french-invasive-isolates 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/applying-direct-aptt-ratio-platelinlsactinfs-permits-identify-rapidly-and-reliably-bleeding-related 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/applying-direct-aptt-ratio-platelinlsactinfs-permits-identify-rapidly-and-reliably-bleeding-related 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/applying-direct-aptt-ratio-platelinlsactinfs-permits-identify-rapidly-and-reliably-bleeding-related 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/melanins-and-melanogenesis-pigment-cells-human-health-and-technological-applications 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/melanins-and-melanogenesis-pigment-cells-human-health-and-technological-applications 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/melanins-and-melanogenesis-pigment-cells-human-health-and-technological-applications 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/morbidity-laparoscopic-radical-cystectomy-analysis-postoperative-complications-multicenter-cohort 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/morbidity-laparoscopic-radical-cystectomy-analysis-postoperative-complications-multicenter-cohort 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/morbidity-laparoscopic-radical-cystectomy-analysis-postoperative-complications-multicenter-cohort 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/understanding-risk-infection-patients-neutropenia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/understanding-risk-infection-patients-neutropenia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/understanding-risk-infection-patients-neutropenia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/diffuse-intra-abdominal-low-grade-fibromyxoid-sarcoma-hepatic-metastases-case-report-and-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/diffuse-intra-abdominal-low-grade-fibromyxoid-sarcoma-hepatic-metastases-case-report-and-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/diffuse-intra-abdominal-low-grade-fibromyxoid-sarcoma-hepatic-metastases-case-report-and-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/role-d4z4-encoded-proteins-osteogenic-differentiation-mesenchymal-stromal-cells-isolated-bone 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/role-d4z4-encoded-proteins-osteogenic-differentiation-mesenchymal-stromal-cells-isolated-bone 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/role-d4z4-encoded-proteins-osteogenic-differentiation-mesenchymal-stromal-cells-isolated-bone 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/art-and-science-personalized-medicine-getting-personal-enough 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/art-and-science-personalized-medicine-getting-personal-enough 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/art-and-science-personalized-medicine-getting-personal-enough 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/subclonal-diversification-primary-breast-cancer-revealed-multiregion-sequencing 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/subclonal-diversification-primary-breast-cancer-revealed-multiregion-sequencing 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/subclonal-diversification-primary-breast-cancer-revealed-multiregion-sequencing 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tumor-infiltrating-lymphocytes-and-associations-pathological-complete-response-and-event-free 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/tumor-infiltrating-lymphocytes-and-associations-pathological-complete-response-and-event-free 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/tumor-infiltrating-lymphocytes-and-associations-pathological-complete-response-and-event-free 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/isolation-and-characterization-human-mesenchymal-stromal-cell-subpopulations-comparison-bone-marrow 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/isolation-and-characterization-human-mesenchymal-stromal-cell-subpopulations-comparison-bone-marrow 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/isolation-and-characterization-human-mesenchymal-stromal-cell-subpopulations-comparison-bone-marrow 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/targeted-therapies-detrimental-treatment-nonsmall-cell-lung-cancer-without-driver-mutations 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/targeted-therapies-detrimental-treatment-nonsmall-cell-lung-cancer-without-driver-mutations 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/targeted-therapies-detrimental-treatment-nonsmall-cell-lung-cancer-without-driver-mutations 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/fertility-issues-young-breast-cancer-patients-what-women-want 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/fertility-issues-young-breast-cancer-patients-what-women-want 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/fertility-issues-young-breast-cancer-patients-what-women-want 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-control-china-challenges-and-opportunities-use-population-based-routine-data-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-control-china-challenges-and-opportunities-use-population-based-routine-data-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-control-china-challenges-and-opportunities-use-population-based-routine-data-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/transient-leukemia-newborn-without-down-syndrome-case-report-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/transient-leukemia-newborn-without-down-syndrome-case-report-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/transient-leukemia-newborn-without-down-syndrome-case-report-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/euthanasia-status-report-2014 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/euthanasia-status-report-2014 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/euthanasia-status-report-2014 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/informed-consent-biobank-research-and-locality-perceptions-breast-cancer-patients-three-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/informed-consent-biobank-research-and-locality-perceptions-breast-cancer-patients-three-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/informed-consent-biobank-research-and-locality-perceptions-breast-cancer-patients-three-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/recurrent-invasive-thymoma-pleural-dissemination-disease-management-and-treatment-possibilities 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/recurrent-invasive-thymoma-pleural-dissemination-disease-management-and-treatment-possibilities 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/recurrent-invasive-thymoma-pleural-dissemination-disease-management-and-treatment-possibilities 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/severe-bilateral-panuveitis-during-melanoma-treatment-dabrafenib-and-trametinib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/severe-bilateral-panuveitis-during-melanoma-treatment-dabrafenib-and-trametinib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/severe-bilateral-panuveitis-during-melanoma-treatment-dabrafenib-and-trametinib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/small-cell-carcinoma-urinary-bladder-retrospective-multicenter-rare-cancer-network-study-107 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/small-cell-carcinoma-urinary-bladder-retrospective-multicenter-rare-cancer-network-study-107 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/small-cell-carcinoma-urinary-bladder-retrospective-multicenter-rare-cancer-network-study-107 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/renal-cysts-novel-complication-crizotinib-treatment-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/renal-cysts-novel-complication-crizotinib-treatment-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/renal-cysts-novel-complication-crizotinib-treatment-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/staphylococcus-aureus-nasal-carriage-among-healthcare-workers-kisangani-democratic-republic-congo 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/staphylococcus-aureus-nasal-carriage-among-healthcare-workers-kisangani-democratic-republic-congo 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/staphylococcus-aureus-nasal-carriage-among-healthcare-workers-kisangani-democratic-republic-congo 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/high-throughput-analysis-human-cytomegalovirus-genome-diversity-highlights-widespread-occurrence 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/high-throughput-analysis-human-cytomegalovirus-genome-diversity-highlights-widespread-occurrence 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/high-throughput-analysis-human-cytomegalovirus-genome-diversity-highlights-widespread-occurrence 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/vulvar-metastasis-bladder-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/vulvar-metastasis-bladder-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/vulvar-metastasis-bladder-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/has-time-come-genomic-tests-guide-use-adjuvant-chemotherapy-node-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/has-time-come-genomic-tests-guide-use-adjuvant-chemotherapy-node-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/has-time-come-genomic-tests-guide-use-adjuvant-chemotherapy-node-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/spurious-decrease-wbc-count-measured-wnr-channel-xn-haematology-analyser-sysmex-could-be-0 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/spurious-decrease-wbc-count-measured-wnr-channel-xn-haematology-analyser-sysmex-could-be-0 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/spurious-decrease-wbc-count-measured-wnr-channel-xn-haematology-analyser-sysmex-could-be-0 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/irf5-rheostat-tumor-infiltrating-lymphocyte-trafficking-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/irf5-rheostat-tumor-infiltrating-lymphocyte-trafficking-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/irf5-rheostat-tumor-infiltrating-lymphocyte-trafficking-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/esrers-white-paper-lung-cancer-screening 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/esrers-white-paper-lung-cancer-screening 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/esrers-white-paper-lung-cancer-screening 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-trials-precision-medicine-through-molecular-profiling-focus-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-trials-precision-medicine-through-molecular-profiling-focus-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-trials-precision-medicine-through-molecular-profiling-focus-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tailoring-therapies-improving-management-early-breast-cancer-st-galleninternational-expert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tailoring-therapies-improving-management-early-breast-cancer-st-galleninternational-expert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tailoring-therapies-improving-management-early-breast-cancer-st-galleninternational-expert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/proof-concept-trial-anti-egfr-antibody-mixture-sym004-patients-squamous-cell-carcinoma-head-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/proof-concept-trial-anti-egfr-antibody-mixture-sym004-patients-squamous-cell-carcinoma-head-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/proof-concept-trial-anti-egfr-antibody-mixture-sym004-patients-squamous-cell-carcinoma-head-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/frequent-somatic-transfer-mitochondrial-dna-nuclear-genome-human-cancer-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/frequent-somatic-transfer-mitochondrial-dna-nuclear-genome-human-cancer-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/frequent-somatic-transfer-mitochondrial-dna-nuclear-genome-human-cancer-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/frequent-incidence-bard1-truncating-mutations-germline-dna-triple-negative-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/frequent-incidence-bard1-truncating-mutations-germline-dna-triple-negative-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/frequent-incidence-bard1-truncating-mutations-germline-dna-triple-negative-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/avoiding-false-positive-antigen-detection-flow-cytometry-blood-cell-derived-microparticles 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/avoiding-false-positive-antigen-detection-flow-cytometry-blood-cell-derived-microparticles 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/avoiding-false-positive-antigen-detection-flow-cytometry-blood-cell-derived-microparticles 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/aging-and-malignant-hemopathies 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/aging-and-malignant-hemopathies 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/aging-and-malignant-hemopathies 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/revisiting-transcriptional-analysis-primary-tumours-and-associated-nodal-metastases-enhanced 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/revisiting-transcriptional-analysis-primary-tumours-and-associated-nodal-metastases-enhanced 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/revisiting-transcriptional-analysis-primary-tumours-and-associated-nodal-metastases-enhanced 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/report-oeci-oncology-days-2014 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/report-oeci-oncology-days-2014 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/report-oeci-oncology-days-2014 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-management-breast-cancer-heterogeneity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-management-breast-cancer-heterogeneity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-management-breast-cancer-heterogeneity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/aromatase-inhibitors-male-breast-cancer-pooled-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/aromatase-inhibitors-male-breast-cancer-pooled-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/aromatase-inhibitors-male-breast-cancer-pooled-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/access-human-tissues-research-and-product-development-eu-regulation-alarming-legal-developments 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/access-human-tissues-research-and-product-development-eu-regulation-alarming-legal-developments 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/access-human-tissues-research-and-product-development-eu-regulation-alarming-legal-developments 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/decoding-regulatory-landscape-melanoma-reveals-teads-regulators-invasive-cell-state 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/decoding-regulatory-landscape-melanoma-reveals-teads-regulators-invasive-cell-state 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/decoding-regulatory-landscape-melanoma-reveals-teads-regulators-invasive-cell-state 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/towards-tuberculosis-elimination-action-framework-low-incidence-countries 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/towards-tuberculosis-elimination-action-framework-low-incidence-countries 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/towards-tuberculosis-elimination-action-framework-low-incidence-countries 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/esrers-white-paper-lung-cancer-screening-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/esrers-white-paper-lung-cancer-screening-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/esrers-white-paper-lung-cancer-screening-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/long-term-hazard-recurrence-her2-breast-cancer-patients-untreated-anti-her2-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/long-term-hazard-recurrence-her2-breast-cancer-patients-untreated-anti-her2-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/long-term-hazard-recurrence-her2-breast-cancer-patients-untreated-anti-her2-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/epidemiology-and-outcome-fungemia-cancer-cohort-infectious-diseases-group-idg-european-organization 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/epidemiology-and-outcome-fungemia-cancer-cohort-infectious-diseases-group-idg-european-organization 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/epidemiology-and-outcome-fungemia-cancer-cohort-infectious-diseases-group-idg-european-organization 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/end-life-sedation-there-alternative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/end-life-sedation-there-alternative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/end-life-sedation-there-alternative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/computer-aided-detection-breast-cancers-using-haar-features-automated-3d-breast-ultrasound 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/computer-aided-detection-breast-cancers-using-haar-features-automated-3d-breast-ultrasound 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/computer-aided-detection-breast-cancers-using-haar-features-automated-3d-breast-ultrasound 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/uncovering-genomic-heterogeneity-multifocal-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/uncovering-genomic-heterogeneity-multifocal-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/uncovering-genomic-heterogeneity-multifocal-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/predicting-anthracycline-benefit-top2a-and-cep17-not-only-also 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/predicting-anthracycline-benefit-top2a-and-cep17-not-only-also 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/predicting-anthracycline-benefit-top2a-and-cep17-not-only-also 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/duration-endocrine-therapy-and-its-impact-results-adjuvant-trials-premenopausal-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/duration-endocrine-therapy-and-its-impact-results-adjuvant-trials-premenopausal-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/duration-endocrine-therapy-and-its-impact-results-adjuvant-trials-premenopausal-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/aging-and-blood-disorders-new-perspectives-new-challenges 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/aging-and-blood-disorders-new-perspectives-new-challenges 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/aging-and-blood-disorders-new-perspectives-new-challenges 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/introduction-thematic-series-targeted-therapies-lung-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/introduction-thematic-series-targeted-therapies-lung-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/introduction-thematic-series-targeted-therapies-lung-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lung-cancer-diagnosis-emergency-department 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lung-cancer-diagnosis-emergency-department 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lung-cancer-diagnosis-emergency-department 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/microrna-expression-autonomous-thyroid-adenomas-correlation-mrna-regulation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/microrna-expression-autonomous-thyroid-adenomas-correlation-mrna-regulation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/microrna-expression-autonomous-thyroid-adenomas-correlation-mrna-regulation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/selective-internal-radiation-therapy-sirt-yttrium-90-resin-microspheres-plus-standard-systemic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/selective-internal-radiation-therapy-sirt-yttrium-90-resin-microspheres-plus-standard-systemic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/selective-internal-radiation-therapy-sirt-yttrium-90-resin-microspheres-plus-standard-systemic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/ras-digestive-oncology-molecular-biology-clinical-implications 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/ras-digestive-oncology-molecular-biology-clinical-implications 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/ras-digestive-oncology-molecular-biology-clinical-implications 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/discrepancies-between-esmo-and-nccn-breast-cancer-guidelines-appraisal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/discrepancies-between-esmo-and-nccn-breast-cancer-guidelines-appraisal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/discrepancies-between-esmo-and-nccn-breast-cancer-guidelines-appraisal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/targeted-agents-cancer-treatment-during-pregnancy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/targeted-agents-cancer-treatment-during-pregnancy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/targeted-agents-cancer-treatment-during-pregnancy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/nfat-1-sp-1-sp-3-and-mir-21-new-regulators-chemokine-c-receptor-7-expression-mature-human-dendritic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/nfat-1-sp-1-sp-3-and-mir-21-new-regulators-chemokine-c-receptor-7-expression-mature-human-dendritic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/nfat-1-sp-1-sp-3-and-mir-21-new-regulators-chemokine-c-receptor-7-expression-mature-human-dendritic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/survey-skin-lightening-practices-and-cosmetics-kigali-rwanda 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/survey-skin-lightening-practices-and-cosmetics-kigali-rwanda 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/survey-skin-lightening-practices-and-cosmetics-kigali-rwanda 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/new-approaches-improving-outcomes-breast-cancer-europe 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/new-approaches-improving-outcomes-breast-cancer-europe 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/new-approaches-improving-outcomes-breast-cancer-europe 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/health-related-quality-life-women-teach-randomised-placebo-controlled-adjuvant-trial-lapatinib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/health-related-quality-life-women-teach-randomised-placebo-controlled-adjuvant-trial-lapatinib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/health-related-quality-life-women-teach-randomised-placebo-controlled-adjuvant-trial-lapatinib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/no-significant-viral-transcription-detected-whole-breast-cancer-transcriptomes 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/no-significant-viral-transcription-detected-whole-breast-cancer-transcriptomes 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/no-significant-viral-transcription-detected-whole-breast-cancer-transcriptomes 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/tumour-educated-circulating-monocytes-are-powerful-candidate-biomarkers-diagnosis-and-disease 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tumour-educated-circulating-monocytes-are-powerful-candidate-biomarkers-diagnosis-and-disease 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tumour-educated-circulating-monocytes-are-powerful-candidate-biomarkers-diagnosis-and-disease 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/regorafenib-assessment-refractory-advanced-colorectal-cancer-regard-c-study-protocol 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/regorafenib-assessment-refractory-advanced-colorectal-cancer-regard-c-study-protocol 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/regorafenib-assessment-refractory-advanced-colorectal-cancer-regard-c-study-protocol 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/mucolytic-agents-can-enhance-her2-receptor-accessibility-89zrtrastuzumab-improving-her2-imaging 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/mucolytic-agents-can-enhance-her2-receptor-accessibility-89zrtrastuzumab-improving-her2-imaging 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/mucolytic-agents-can-enhance-her2-receptor-accessibility-89zrtrastuzumab-improving-her2-imaging 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tumour-targeting-and-radiation-dose-radioimmunotherapy-90y-rituximab-cd20-b-cell-lymphoma-predicted 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tumour-targeting-and-radiation-dose-radioimmunotherapy-90y-rituximab-cd20-b-cell-lymphoma-predicted 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tumour-targeting-and-radiation-dose-radioimmunotherapy-90y-rituximab-cd20-b-cell-lymphoma-predicted 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/advances-target-therapy-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/advances-target-therapy-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/advances-target-therapy-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-trial-volasertib-polo-kinase-inhibitor-plus-platinum-agents-solid-tumors-safety 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-trial-volasertib-polo-kinase-inhibitor-plus-platinum-agents-solid-tumors-safety 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-trial-volasertib-polo-kinase-inhibitor-plus-platinum-agents-solid-tumors-safety 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/erratum-preoperative-chemosensitivity-testing-predictor-treatment-benefit-adjuvant-stage-iii-colon 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/erratum-preoperative-chemosensitivity-testing-predictor-treatment-benefit-adjuvant-stage-iii-colon 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/erratum-preoperative-chemosensitivity-testing-predictor-treatment-benefit-adjuvant-stage-iii-colon 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/influence-lumbar-plexus-block-proximal-modular-megaprostheses-metastatic-bone-disease-femur 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/influence-lumbar-plexus-block-proximal-modular-megaprostheses-metastatic-bone-disease-femur 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/influence-lumbar-plexus-block-proximal-modular-megaprostheses-metastatic-bone-disease-femur 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-towards-evolution-minimalist-locoregional-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-towards-evolution-minimalist-locoregional-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-towards-evolution-minimalist-locoregional-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/eortc-melanoma-group-achievements 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/eortc-melanoma-group-achievements 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/eortc-melanoma-group-achievements 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tyrosinase-related-protein-1-tyrp1-gp75-human-cutaneous-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tyrosinase-related-protein-1-tyrp1-gp75-human-cutaneous-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tyrosinase-related-protein-1-tyrp1-gp75-human-cutaneous-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/rank-ligand-rankl-expression-young-breast-cancer-patients-and-during-pregnancy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/rank-ligand-rankl-expression-young-breast-cancer-patients-and-during-pregnancy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/rank-ligand-rankl-expression-young-breast-cancer-patients-and-during-pregnancy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/guidelines-time-event-end-point-definitions-breast-cancer-trials-results-datecan-initiative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/guidelines-time-event-end-point-definitions-breast-cancer-trials-results-datecan-initiative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/guidelines-time-event-end-point-definitions-breast-cancer-trials-results-datecan-initiative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/adult-onset-asynchronous-multifocal-eosinophilic-granuloma-bone-11-year-follow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adult-onset-asynchronous-multifocal-eosinophilic-granuloma-bone-11-year-follow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adult-onset-asynchronous-multifocal-eosinophilic-granuloma-bone-11-year-follow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/penile-rehabilitation-after-pelvic-cancer-surgery 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/penile-rehabilitation-after-pelvic-cancer-surgery 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/penile-rehabilitation-after-pelvic-cancer-surgery 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lipoprotein-lipase-snps-rs13702-and-rs301-correlate-clinical-outcome-chronic-lymphocytic-leukemia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lipoprotein-lipase-snps-rs13702-and-rs301-correlate-clinical-outcome-chronic-lymphocytic-leukemia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lipoprotein-lipase-snps-rs13702-and-rs301-correlate-clinical-outcome-chronic-lymphocytic-leukemia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/honor-professor-philippe-martiat 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/honor-professor-philippe-martiat 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/honor-professor-philippe-martiat 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/erratum-efficacy-eribulin-women-metastatic-breast-cancer-pooled-analysis-two-phase-3-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/erratum-efficacy-eribulin-women-metastatic-breast-cancer-pooled-analysis-two-phase-3-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/erratum-efficacy-eribulin-women-metastatic-breast-cancer-pooled-analysis-two-phase-3-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pulmonary-malignancies-pulmonary-complications-hiv-edited-charles-feldman-eva-polverino-julio 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pulmonary-malignancies-pulmonary-complications-hiv-edited-charles-feldman-eva-polverino-julio 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pulmonary-malignancies-pulmonary-complications-hiv-edited-charles-feldman-eva-polverino-julio 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/therapies-ciblees-quel-traitement-pour-quel-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/therapies-ciblees-quel-traitement-pour-quel-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/therapies-ciblees-quel-traitement-pour-quel-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/sculier-j-p-anticancer-treatment-advanced-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/sculier-j-p-anticancer-treatment-advanced-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/sculier-j-p-anticancer-treatment-advanced-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/thoracic-oncology-european-respiratory-roadmap-recommendations-future-respiratory-medicine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/thoracic-oncology-european-respiratory-roadmap-recommendations-future-respiratory-medicine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/thoracic-oncology-european-respiratory-roadmap-recommendations-future-respiratory-medicine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/15th-annual-workshop-thoracic-oncology-jaot 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/15th-annual-workshop-thoracic-oncology-jaot 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/15th-annual-workshop-thoracic-oncology-jaot 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/minimal-residual-disease-and-circulating-tumor-cells-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/minimal-residual-disease-and-circulating-tumor-cells-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/minimal-residual-disease-and-circulating-tumor-cells-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/adjuvant-systemic-therapy-breast-cancer-quo-vadis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adjuvant-systemic-therapy-breast-cancer-quo-vadis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adjuvant-systemic-therapy-breast-cancer-quo-vadis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pregnancy-after-breast-cancer-are-young-patients-willing-participate-clinical-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pregnancy-after-breast-cancer-are-young-patients-willing-participate-clinical-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pregnancy-after-breast-cancer-are-young-patients-willing-participate-clinical-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tumour-infiltrating-lymphocytes-tils-breast-cancer-during-pregnancy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tumour-infiltrating-lymphocytes-tils-breast-cancer-during-pregnancy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tumour-infiltrating-lymphocytes-tils-breast-cancer-during-pregnancy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/risk-misinterpretation-ebola-virus-pcr-results-after-rvsv-zebov-gp-vaccination 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/risk-misinterpretation-ebola-virus-pcr-results-after-rvsv-zebov-gp-vaccination 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/risk-misinterpretation-ebola-virus-pcr-results-after-rvsv-zebov-gp-vaccination 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/non-myeloablative-allogeneic-hematopoietic-cell-transplantation-following-fludarabine-plus-2-gy-tbi 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/non-myeloablative-allogeneic-hematopoietic-cell-transplantation-following-fludarabine-plus-2-gy-tbi 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/non-myeloablative-allogeneic-hematopoietic-cell-transplantation-following-fludarabine-plus-2-gy-tbi 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/high-her2-expression-correlates-response-combination-lapatinib-and-trastuzumab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/high-her2-expression-correlates-response-combination-lapatinib-and-trastuzumab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/high-her2-expression-correlates-response-combination-lapatinib-and-trastuzumab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/admitting-lung-cancer-patients-intensive-care-organ-dysfunction-complex-decision-process 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/admitting-lung-cancer-patients-intensive-care-organ-dysfunction-complex-decision-process 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/admitting-lung-cancer-patients-intensive-care-organ-dysfunction-complex-decision-process 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-egfr-mutated-nonsmall-cell-lung-carcinoma-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-egfr-mutated-nonsmall-cell-lung-carcinoma-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-egfr-mutated-nonsmall-cell-lung-carcinoma-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evaluating-pharmacokinetics-and-pharmacodynamics-everolimus-treating-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluating-pharmacokinetics-and-pharmacodynamics-everolimus-treating-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluating-pharmacokinetics-and-pharmacodynamics-everolimus-treating-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/new-generations-targeted-therapies-fighting-resistance-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/new-generations-targeted-therapies-fighting-resistance-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/new-generations-targeted-therapies-fighting-resistance-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/metabolic-disorders-associated-use-targeted-cancer-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/metabolic-disorders-associated-use-targeted-cancer-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/metabolic-disorders-associated-use-targeted-cancer-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/intratumor-heterogeneity-and-clonal-evolution-aggressive-ptc-and-matched-metastases 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/intratumor-heterogeneity-and-clonal-evolution-aggressive-ptc-and-matched-metastases 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/intratumor-heterogeneity-and-clonal-evolution-aggressive-ptc-and-matched-metastases 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/triptorelin-relief-lower-urinary-tract-symptoms-advanced-prostate-cancer-patients-result-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/triptorelin-relief-lower-urinary-tract-symptoms-advanced-prostate-cancer-patients-result-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/triptorelin-relief-lower-urinary-tract-symptoms-advanced-prostate-cancer-patients-result-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/transfer-communication-skills-workplace-impact-38-hour-communication-skills-training-program 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/transfer-communication-skills-workplace-impact-38-hour-communication-skills-training-program 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/transfer-communication-skills-workplace-impact-38-hour-communication-skills-training-program 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prognosis-neutropenic-patients-admitted-intensive-care-unit 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prognosis-neutropenic-patients-admitted-intensive-care-unit 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prognosis-neutropenic-patients-admitted-intensive-care-unit 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/intraperitoneal-follicular-dendritic-cell-sarcoma-role-chemotherapy-and-bone-marrow 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/intraperitoneal-follicular-dendritic-cell-sarcoma-role-chemotherapy-and-bone-marrow 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/intraperitoneal-follicular-dendritic-cell-sarcoma-role-chemotherapy-and-bone-marrow 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/mri-targeted-biopsies-versus-systematic-transrectal-ultrasound-guided-biopsies-diagnosis-localized 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/mri-targeted-biopsies-versus-systematic-transrectal-ultrasound-guided-biopsies-diagnosis-localized 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/mri-targeted-biopsies-versus-systematic-transrectal-ultrasound-guided-biopsies-diagnosis-localized 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/y90-radioembolization-colorectal-cancer-liver-metastases-response-assessment-contrast-enhanced 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/y90-radioembolization-colorectal-cancer-liver-metastases-response-assessment-contrast-enhanced 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/y90-radioembolization-colorectal-cancer-liver-metastases-response-assessment-contrast-enhanced 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/pooled-analysis-surgical-treatment-colorectal-cancer-liver-metastases 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/pooled-analysis-surgical-treatment-colorectal-cancer-liver-metastases 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/pooled-analysis-surgical-treatment-colorectal-cancer-liver-metastases 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/pik3ca-mutations-are-associated-decreased-benefit-neoadjuvant-human-epidermal-growth-factor 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/pik3ca-mutations-are-associated-decreased-benefit-neoadjuvant-human-epidermal-growth-factor 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/pik3ca-mutations-are-associated-decreased-benefit-neoadjuvant-human-epidermal-growth-factor 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/prospective-validation-obtained-similar-group-patients-and-similar-high-throughput-biological-tests 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prospective-validation-obtained-similar-group-patients-and-similar-high-throughput-biological-tests 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prospective-validation-obtained-similar-group-patients-and-similar-high-throughput-biological-tests 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/medical-anticancer-treatment-lung-cancer-associated-comorbidities-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/medical-anticancer-treatment-lung-cancer-associated-comorbidities-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/medical-anticancer-treatment-lung-cancer-associated-comorbidities-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-iii-open-label-randomized-study-eribulin-mesylate-versus-capecitabine-patients-locally 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-iii-open-label-randomized-study-eribulin-mesylate-versus-capecitabine-patients-locally 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-iii-open-label-randomized-study-eribulin-mesylate-versus-capecitabine-patients-locally 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/microvesicles-and-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/microvesicles-and-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/microvesicles-and-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/ibrutinib-major-breakthrough-treatment-cll-and-other-lymphoproliferative-disorders 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/ibrutinib-major-breakthrough-treatment-cll-and-other-lymphoproliferative-disorders 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/ibrutinib-major-breakthrough-treatment-cll-and-other-lymphoproliferative-disorders 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/rituximab-maintenance-obviates-poor-prognosis-associated-circulating-lymphoma-cells-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/rituximab-maintenance-obviates-poor-prognosis-associated-circulating-lymphoma-cells-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/rituximab-maintenance-obviates-poor-prognosis-associated-circulating-lymphoma-cells-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/anemia-elderly 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/anemia-elderly 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/anemia-elderly 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/opposite-prognostic-significance-cellular-and-serum-circulating-microrna-150-chronic-lymphocytic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/opposite-prognostic-significance-cellular-and-serum-circulating-microrna-150-chronic-lymphocytic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/opposite-prognostic-significance-cellular-and-serum-circulating-microrna-150-chronic-lymphocytic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/results-phase-ii-study-bendamustine-and-ofatumumab-untreated-indolent-b-cell-non-hodgkin-s-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/results-phase-ii-study-bendamustine-and-ofatumumab-untreated-indolent-b-cell-non-hodgkin-s-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/results-phase-ii-study-bendamustine-and-ofatumumab-untreated-indolent-b-cell-non-hodgkin-s-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/enabling-semantic-interoperability-multi-centric-clinical-trials-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/enabling-semantic-interoperability-multi-centric-clinical-trials-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/enabling-semantic-interoperability-multi-centric-clinical-trials-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/comparative-epidemiology-staphylococcus-epidermidis-isolates-patients-catheter-related-bacteremia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/comparative-epidemiology-staphylococcus-epidermidis-isolates-patients-catheter-related-bacteremia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/comparative-epidemiology-staphylococcus-epidermidis-isolates-patients-catheter-related-bacteremia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/comparison-antibiotic-activities-daptomycin-vancomycin-and-investigational-fluoroquinolone 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/comparison-antibiotic-activities-daptomycin-vancomycin-and-investigational-fluoroquinolone 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/comparison-antibiotic-activities-daptomycin-vancomycin-and-investigational-fluoroquinolone 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/phylogenetic-analysis-staphylococcus-aureus-cc398-reveals-sub-lineage-epidemiologically-associated 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/phylogenetic-analysis-staphylococcus-aureus-cc398-reveals-sub-lineage-epidemiologically-associated 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/phylogenetic-analysis-staphylococcus-aureus-cc398-reveals-sub-lineage-epidemiologically-associated 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/chronic-exposure-low-dose-radiation-chernobyl-favors-adaptation-oxidative-stress-birds 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/chronic-exposure-low-dose-radiation-chernobyl-favors-adaptation-oxidative-stress-birds 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/chronic-exposure-low-dose-radiation-chernobyl-favors-adaptation-oxidative-stress-birds 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/electron-paramagnetic-resonance-spectrometry-and-imaging-melanomas-comparison-between-pigmented-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/electron-paramagnetic-resonance-spectrometry-and-imaging-melanomas-comparison-between-pigmented-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/electron-paramagnetic-resonance-spectrometry-and-imaging-melanomas-comparison-between-pigmented-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/influence-paramagnetic-melanin-mri-contrast-melanoma-combined-high-field-117-t-mri-and-epr-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/influence-paramagnetic-melanin-mri-contrast-melanoma-combined-high-field-117-t-mri-and-epr-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/influence-paramagnetic-melanin-mri-contrast-melanoma-combined-high-field-117-t-mri-and-epr-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/epitheliomas-bronchiques-petites-cellules-et-metastases-cerebrales-de-leur-traitement-leur 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/epitheliomas-bronchiques-petites-cellules-et-metastases-cerebrales-de-leur-traitement-leur 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/epitheliomas-bronchiques-petites-cellules-et-metastases-cerebrales-de-leur-traitement-leur 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/indications-non-oncologiques-quelles-indications-en-2014 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/indications-non-oncologiques-quelles-indications-en-2014 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/indications-non-oncologiques-quelles-indications-en-2014 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/febrile-neutropenia-pocket-books-cancer-supportive-care-2014-springer-healthcare 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/febrile-neutropenia-pocket-books-cancer-supportive-care-2014-springer-healthcare 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/febrile-neutropenia-pocket-books-cancer-supportive-care-2014-springer-healthcare 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/supportive-care-cancer-patients-unifying-concept 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/supportive-care-cancer-patients-unifying-concept 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/supportive-care-cancer-patients-unifying-concept 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/adverse-events-targeted-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adverse-events-targeted-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adverse-events-targeted-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/bladder-sparing-robot-assisted-laparoscopic-en-bloc-resection-urachus-and-umbilicus-urachal-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bladder-sparing-robot-assisted-laparoscopic-en-bloc-resection-urachus-and-umbilicus-urachal-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bladder-sparing-robot-assisted-laparoscopic-en-bloc-resection-urachus-and-umbilicus-urachal-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/solitary-rectal-ulcer-anal-seeds-discharge-after-transperineal-interstitial-brachytherapy-prostate 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/solitary-rectal-ulcer-anal-seeds-discharge-after-transperineal-interstitial-brachytherapy-prostate 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/solitary-rectal-ulcer-anal-seeds-discharge-after-transperineal-interstitial-brachytherapy-prostate 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-and-cost-effectiveness-hexaminolevulinate-guided-blue-light-cystoscopy-evidence-review-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-and-cost-effectiveness-hexaminolevulinate-guided-blue-light-cystoscopy-evidence-review-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-and-cost-effectiveness-hexaminolevulinate-guided-blue-light-cystoscopy-evidence-review-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/head-docking-single-stage-robotic-cortical-sparing-adrenalectomy-bilateral-pheochromocytoma-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/head-docking-single-stage-robotic-cortical-sparing-adrenalectomy-bilateral-pheochromocytoma-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/head-docking-single-stage-robotic-cortical-sparing-adrenalectomy-bilateral-pheochromocytoma-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lower-urinary-tract-dysfunction-after-radical-hysterectomy-cervical-cancer-zanaty-m-peltier-van 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lower-urinary-tract-dysfunction-after-radical-hysterectomy-cervical-cancer-zanaty-m-peltier-van 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lower-urinary-tract-dysfunction-after-radical-hysterectomy-cervical-cancer-zanaty-m-peltier-van 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/eau-policy-live-surgery-events 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/eau-policy-live-surgery-events 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/eau-policy-live-surgery-events 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/long-term-analysis-oncological-outcomes-after-laparoscopic-radical-cystectomy-europe-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/long-term-analysis-oncological-outcomes-after-laparoscopic-radical-cystectomy-europe-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/long-term-analysis-oncological-outcomes-after-laparoscopic-radical-cystectomy-europe-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/bi-focal-retroperitoneal-paraganglioma-young-patient-case-report-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bi-focal-retroperitoneal-paraganglioma-young-patient-case-report-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bi-focal-retroperitoneal-paraganglioma-young-patient-case-report-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lower-urinary-tract-dysfunction-after-nerve-sparing-radical-hysterectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lower-urinary-tract-dysfunction-after-nerve-sparing-radical-hysterectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lower-urinary-tract-dysfunction-after-nerve-sparing-radical-hysterectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prostate-sparing-robot-assisted-laparoscopic-treatment-leiomyoma-prostate-aoun-f-somerhausen-n-van 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prostate-sparing-robot-assisted-laparoscopic-treatment-leiomyoma-prostate-aoun-f-somerhausen-n-van 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prostate-sparing-robot-assisted-laparoscopic-treatment-leiomyoma-prostate-aoun-f-somerhausen-n-van 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/adjuvant-and-neoadjuvant-chemotherapy-regimens-breast-cancer-summary-bsmo-breast-cancer-task-force 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adjuvant-and-neoadjuvant-chemotherapy-regimens-breast-cancer-summary-bsmo-breast-cancer-task-force 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adjuvant-and-neoadjuvant-chemotherapy-regimens-breast-cancer-summary-bsmo-breast-cancer-task-force 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/huisartsen-staan-machteloos-tegenover-kanker-artsenkran 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/huisartsen-staan-machteloos-tegenover-kanker-artsenkran 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/huisartsen-staan-machteloos-tegenover-kanker-artsenkran 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/en-cancerologie-la-medecine-personnalisee-est-en-route-journal-du-medecin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/en-cancerologie-la-medecine-personnalisee-est-en-route-journal-du-medecin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/en-cancerologie-la-medecine-personnalisee-est-en-route-journal-du-medecin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cardiac-metastase-soft-tissue-sarcoma-case-report-and-review-literature 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/cardiac-metastase-soft-tissue-sarcoma-case-report-and-review-literature 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/cardiac-metastase-soft-tissue-sarcoma-case-report-and-review-literature 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/stratified-medicine-call-action 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/stratified-medicine-call-action 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/stratified-medicine-call-action 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/thrombo-embolic-events-cancer-patients-impaired-renal-function-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/thrombo-embolic-events-cancer-patients-impaired-renal-function-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/thrombo-embolic-events-cancer-patients-impaired-renal-function-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/foreword-edition-treatment-strategies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/foreword-edition-treatment-strategies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/foreword-edition-treatment-strategies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/stratified-medicine-call-action-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/stratified-medicine-call-action-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/stratified-medicine-call-action-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-side-effects-medical-cancer-therapy-prevention-and-treatment-ed-mario-dicato-chapter 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-side-effects-medical-cancer-therapy-prevention-and-treatment-ed-mario-dicato-chapter 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-side-effects-medical-cancer-therapy-prevention-and-treatment-ed-mario-dicato-chapter 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/histiocytose-agressive-cellules-de-langerhans-20-ans-apres-un-cancer-du-sein-propos-d-un-cas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/histiocytose-agressive-cellules-de-langerhans-20-ans-apres-un-cancer-du-sein-propos-d-un-cas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/histiocytose-agressive-cellules-de-langerhans-20-ans-apres-un-cancer-du-sein-propos-d-un-cas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/prophylaxis-febrile-neutropenia-adults-receiving-chemotherapy-needs-be-adapted-risk 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prophylaxis-febrile-neutropenia-adults-receiving-chemotherapy-needs-be-adapted-risk 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prophylaxis-febrile-neutropenia-adults-receiving-chemotherapy-needs-be-adapted-risk 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/supportive-care-constant-state-changing-we-need-adjust-it 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/supportive-care-constant-state-changing-we-need-adjust-it 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/supportive-care-constant-state-changing-we-need-adjust-it 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/high-genetic-diversity-methicillin-susceptible-staphylococcus-aureus-mssa-humans-and-animals 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/high-genetic-diversity-methicillin-susceptible-staphylococcus-aureus-mssa-humans-and-animals 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/high-genetic-diversity-methicillin-susceptible-staphylococcus-aureus-mssa-humans-and-animals 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/impact-rapid-molecular-screening-hospital-admission-nosocomial-transmission-methicillin-resistant 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/impact-rapid-molecular-screening-hospital-admission-nosocomial-transmission-methicillin-resistant 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/impact-rapid-molecular-screening-hospital-admission-nosocomial-transmission-methicillin-resistant 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/genetic-characteristics-and-antimicrobial-resistance-staphylococcus-epidermidis-isolates-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/genetic-characteristics-and-antimicrobial-resistance-staphylococcus-epidermidis-isolates-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/genetic-characteristics-and-antimicrobial-resistance-staphylococcus-epidermidis-isolates-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/identification-filamentous-fungi-isolates-maldi-tof-mass-spectrometry-clinical-evaluation-extended 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/identification-filamentous-fungi-isolates-maldi-tof-mass-spectrometry-clinical-evaluation-extended 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/identification-filamentous-fungi-isolates-maldi-tof-mass-spectrometry-clinical-evaluation-extended 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/bordetella-pertussis-seroprevalence-belgian-adults-aged-20-39-years-2012 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/bordetella-pertussis-seroprevalence-belgian-adults-aged-20-39-years-2012 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/bordetella-pertussis-seroprevalence-belgian-adults-aged-20-39-years-2012 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/simple-and-rapid-protocol-non-enzymatically-dissociate-fresh-human-tissues-analysis-infiltrating 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/simple-and-rapid-protocol-non-enzymatically-dissociate-fresh-human-tissues-analysis-infiltrating 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/simple-and-rapid-protocol-non-enzymatically-dissociate-fresh-human-tissues-analysis-infiltrating 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/systematic-qualitative-review-randomised-trials-conducted-nsclc-noninferiority-or-equivalence 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/systematic-qualitative-review-randomised-trials-conducted-nsclc-noninferiority-or-equivalence 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/systematic-qualitative-review-randomised-trials-conducted-nsclc-noninferiority-or-equivalence 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-effect-epidural-analgesia-flap-healing-after-breast-reconstruction-pedicled-transverse 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-effect-epidural-analgesia-flap-healing-after-breast-reconstruction-pedicled-transverse 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-effect-epidural-analgesia-flap-healing-after-breast-reconstruction-pedicled-transverse 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/topoisomerase-inhibitors-metastatic-breast-cancer-overview-current-practice-and-future-development 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/topoisomerase-inhibitors-metastatic-breast-cancer-overview-current-practice-and-future-development 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/topoisomerase-inhibitors-metastatic-breast-cancer-overview-current-practice-and-future-development 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impressive-response-eribulin-endocrine-and-chemotherapy-resistant-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/impressive-response-eribulin-endocrine-and-chemotherapy-resistant-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/impressive-response-eribulin-endocrine-and-chemotherapy-resistant-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/belgian-society-medical-oncology-bsmo-task-force-breast-cancer-survivorship 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/belgian-society-medical-oncology-bsmo-task-force-breast-cancer-survivorship 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/belgian-society-medical-oncology-bsmo-task-force-breast-cancer-survivorship 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/what-your-diagnosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/what-your-diagnosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/what-your-diagnosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/circulating-tumor-cells-and-circulating-tumor-dna-precision-medicine-dream-or-reality 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/circulating-tumor-cells-and-circulating-tumor-dna-precision-medicine-dream-or-reality 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/circulating-tumor-cells-and-circulating-tumor-dna-precision-medicine-dream-or-reality 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-validity-circulating-tumour-cells-patients-metastatic-breast-cancer-pooled-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-validity-circulating-tumour-cells-patients-metastatic-breast-cancer-pooled-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-validity-circulating-tumour-cells-patients-metastatic-breast-cancer-pooled-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/multigene-assays-late-recurrence-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/multigene-assays-late-recurrence-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/multigene-assays-late-recurrence-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/semiautomated-isolation-and-molecular-characterisation-single-or-highly-purified-tumour-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/semiautomated-isolation-and-molecular-characterisation-single-or-highly-purified-tumour-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/semiautomated-isolation-and-molecular-characterisation-single-or-highly-purified-tumour-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-new-standardized-enzymatic-isolation-protocol-human-umbilical-cord-derived-stem-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-new-standardized-enzymatic-isolation-protocol-human-umbilical-cord-derived-stem-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-new-standardized-enzymatic-isolation-protocol-human-umbilical-cord-derived-stem-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/rare-case-prostatic-extra-gonadal-germ-cell-tumor-young-adult-review-literature 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/rare-case-prostatic-extra-gonadal-germ-cell-tumor-young-adult-review-literature 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/rare-case-prostatic-extra-gonadal-germ-cell-tumor-young-adult-review-literature 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/prospective-non-interventional-multicentre-observational-trial-first-line-anti-cancer-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prospective-non-interventional-multicentre-observational-trial-first-line-anti-cancer-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prospective-non-interventional-multicentre-observational-trial-first-line-anti-cancer-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/open-label-phase-2-study-evaluating-efficacy-and-safety-anti-igf-1r-antibody-cixutumumab-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/open-label-phase-2-study-evaluating-efficacy-and-safety-anti-igf-1r-antibody-cixutumumab-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/open-label-phase-2-study-evaluating-efficacy-and-safety-anti-igf-1r-antibody-cixutumumab-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/multicenter-phase-1-study-emd-525797-di17e6-novel-humanized-monoclonal-antibody-targeting-av 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/multicenter-phase-1-study-emd-525797-di17e6-novel-humanized-monoclonal-antibody-targeting-av 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/multicenter-phase-1-study-emd-525797-di17e6-novel-humanized-monoclonal-antibody-targeting-av 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/aflibercept-versus-placebo-combination-docetaxel-and-prednisone-treatment-men-metastatic-castration 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/aflibercept-versus-placebo-combination-docetaxel-and-prednisone-treatment-men-metastatic-castration 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/aflibercept-versus-placebo-combination-docetaxel-and-prednisone-treatment-men-metastatic-castration 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/imbalance-between-supply-and-need-medical-oncologists-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/imbalance-between-supply-and-need-medical-oncologists-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/imbalance-between-supply-and-need-medical-oncologists-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/contributions-spectct-imaging-lymphoscintigraphic-investigations-lower-limb-lymphedema 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/contributions-spectct-imaging-lymphoscintigraphic-investigations-lower-limb-lymphedema 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/contributions-spectct-imaging-lymphoscintigraphic-investigations-lower-limb-lymphedema 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/reproducibility-lymphoscintigraphic-evaluation-upper-limb 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reproducibility-lymphoscintigraphic-evaluation-upper-limb 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reproducibility-lymphoscintigraphic-evaluation-upper-limb 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/short-time-effects-radiotherapy-lymphatic-vessels-and-restorative-lymphatic-pathways-experimental 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/short-time-effects-radiotherapy-lymphatic-vessels-and-restorative-lymphatic-pathways-experimental 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/short-time-effects-radiotherapy-lymphatic-vessels-and-restorative-lymphatic-pathways-experimental 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/le-cours-du-groupe-d-oncologie-thoracique-de-la-societe-de-pneumologie-de-langue-francaisegolf-et 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/le-cours-du-groupe-d-oncologie-thoracique-de-la-societe-de-pneumologie-de-langue-francaisegolf-et 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/le-cours-du-groupe-d-oncologie-thoracique-de-la-societe-de-pneumologie-de-langue-francaisegolf-et 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/classification-tnm-du-cancer-bronchique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/classification-tnm-du-cancer-bronchique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/classification-tnm-du-cancer-bronchique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evaluating-physiological-reserves-older-patients-cancer-value-potential-biomarkers-aging 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluating-physiological-reserves-older-patients-cancer-value-potential-biomarkers-aging 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluating-physiological-reserves-older-patients-cancer-value-potential-biomarkers-aging 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/case-report-mammary-and-rectal-metastases-ovarian-cancer-report-two-cases-and-review-literature 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/case-report-mammary-and-rectal-metastases-ovarian-cancer-report-two-cases-and-review-literature 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/case-report-mammary-and-rectal-metastases-ovarian-cancer-report-two-cases-and-review-literature 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/biology-breast-cancer-young-women 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/biology-breast-cancer-young-women 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/biology-breast-cancer-young-women 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/comprehensive-review-contemporary-role-local-treatment-primary-tumor-andor-metastases-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/comprehensive-review-contemporary-role-local-treatment-primary-tumor-andor-metastases-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/comprehensive-review-contemporary-role-local-treatment-primary-tumor-andor-metastases-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lower-urinary-tract-dysfunction-pelvic-gynecologic-cancer-role-urodynamics 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lower-urinary-tract-dysfunction-pelvic-gynecologic-cancer-role-urodynamics 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lower-urinary-tract-dysfunction-pelvic-gynecologic-cancer-role-urodynamics 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/label-free-phenotyping-peripheral-blood-lymphocytes-infrared-imaging 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/label-free-phenotyping-peripheral-blood-lymphocytes-infrared-imaging 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/label-free-phenotyping-peripheral-blood-lymphocytes-infrared-imaging 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/optimising-translational-oncology-clinical-practice-strategies-accelerate-progress-drug-development 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/optimising-translational-oncology-clinical-practice-strategies-accelerate-progress-drug-development 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/optimising-translational-oncology-clinical-practice-strategies-accelerate-progress-drug-development 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/tumor-infiltrating-lymphocytes-and-response-neoadjuvant-chemotherapy-or-without-carboplatin-human 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tumor-infiltrating-lymphocytes-and-response-neoadjuvant-chemotherapy-or-without-carboplatin-human 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tumor-infiltrating-lymphocytes-and-response-neoadjuvant-chemotherapy-or-without-carboplatin-human 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/myeloperoxidase-oxidized-ldl-interferes-endothelial-cell-motility-through-mir-22-and-heme-oxygenase 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/myeloperoxidase-oxidized-ldl-interferes-endothelial-cell-motility-through-mir-22-and-heme-oxygenase 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/myeloperoxidase-oxidized-ldl-interferes-endothelial-cell-motility-through-mir-22-and-heme-oxygenase 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/optimizing-use-pet-selective-internal-radiation-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/optimizing-use-pet-selective-internal-radiation-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/optimizing-use-pet-selective-internal-radiation-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/hurdles-and-delays-access-anti-cancer-drugs-europe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/hurdles-and-delays-access-anti-cancer-drugs-europe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/hurdles-and-delays-access-anti-cancer-drugs-europe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/exploratory-analysis-factors-leading-delays-cancer-drug-reimbursement-european-union-trastuzumab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/exploratory-analysis-factors-leading-delays-cancer-drug-reimbursement-european-union-trastuzumab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/exploratory-analysis-factors-leading-delays-cancer-drug-reimbursement-european-union-trastuzumab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/global-histone-deacetylase-enzymatic-activity-independent-prognostic-marker-associated-shorter 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/global-histone-deacetylase-enzymatic-activity-independent-prognostic-marker-associated-shorter 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/global-histone-deacetylase-enzymatic-activity-independent-prognostic-marker-associated-shorter 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/contribution-mineralogical-analysis-thoraciconcology-example-asbestos-answer-morelle-et-al 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/contribution-mineralogical-analysis-thoraciconcology-example-asbestos-answer-morelle-et-al 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/contribution-mineralogical-analysis-thoraciconcology-example-asbestos-answer-morelle-et-al 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/patient-lung-cancer-intensive-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/patient-lung-cancer-intensive-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/patient-lung-cancer-intensive-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/rate-and-patterns-icu-admission-among-colorectal-cancer-patients-single-center-experience 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/rate-and-patterns-icu-admission-among-colorectal-cancer-patients-single-center-experience 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/rate-and-patterns-icu-admission-among-colorectal-cancer-patients-single-center-experience 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/new-therapeutic-strategies-lung-cancer-preface-du-livre-editors-s-peters-b-besse-springer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/new-therapeutic-strategies-lung-cancer-preface-du-livre-editors-s-peters-b-besse-springer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/new-therapeutic-strategies-lung-cancer-preface-du-livre-editors-s-peters-b-besse-springer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/notwithstanding-fact-no-breaking-practice-changing-studies-were-presented-sessions-devoted 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/notwithstanding-fact-no-breaking-practice-changing-studies-were-presented-sessions-devoted 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/notwithstanding-fact-no-breaking-practice-changing-studies-were-presented-sessions-devoted 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/beyond-trastuzumab-and-lapatinib-new-options-her2-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/beyond-trastuzumab-and-lapatinib-new-options-her2-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/beyond-trastuzumab-and-lapatinib-new-options-her2-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/emerging-targeted-agents-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/emerging-targeted-agents-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/emerging-targeted-agents-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/personalized-therapy-breast-cancer-dream-or-reality 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/personalized-therapy-breast-cancer-dream-or-reality 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/personalized-therapy-breast-cancer-dream-or-reality 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/effect-visceral-metastases-efficacy-and-safety-everolimus-postmenopausal-women-advanced-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/effect-visceral-metastases-efficacy-and-safety-everolimus-postmenopausal-women-advanced-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/effect-visceral-metastases-efficacy-and-safety-everolimus-postmenopausal-women-advanced-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/personalised-cancer-management-closer-not-here-yet 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/personalised-cancer-management-closer-not-here-yet 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/personalised-cancer-management-closer-not-here-yet 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/everolimus-plus-exemestane-postmenopausal-patients-hr-breast-cancer-bolero-2-final-progression-free 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/everolimus-plus-exemestane-postmenopausal-patients-hr-breast-cancer-bolero-2-final-progression-free 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/everolimus-plus-exemestane-postmenopausal-patients-hr-breast-cancer-bolero-2-final-progression-free 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/health-related-quality-life-and-disease-symptoms-postmenopausal-women-hr-her2-advanced-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/health-related-quality-life-and-disease-symptoms-postmenopausal-women-hr-her2-advanced-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/health-related-quality-life-and-disease-symptoms-postmenopausal-women-hr-her2-advanced-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/safety-and-efficacy-everolimus-exemestane-vs-exemestane-alone-elderly-patients-her2-negative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/safety-and-efficacy-everolimus-exemestane-vs-exemestane-alone-elderly-patients-her2-negative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/safety-and-efficacy-everolimus-exemestane-vs-exemestane-alone-elderly-patients-her2-negative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/effect-age-breast-cancer-outcomes-women-human-epidermal-growth-factor-receptor-2-positive-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/effect-age-breast-cancer-outcomes-women-human-epidermal-growth-factor-receptor-2-positive-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/effect-age-breast-cancer-outcomes-women-human-epidermal-growth-factor-receptor-2-positive-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/41st-david-karnofsky-memorial-award-lecture-academic-research-worldwide-quo-vadis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/41st-david-karnofsky-memorial-award-lecture-academic-research-worldwide-quo-vadis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/41st-david-karnofsky-memorial-award-lecture-academic-research-worldwide-quo-vadis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/central-pathology-laboratory-review-her2-and-er-early-breast-cancer-altto-trial-big-2-06ncctg-n063d 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/central-pathology-laboratory-review-her2-and-er-early-breast-cancer-altto-trial-big-2-06ncctg-n063d 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/central-pathology-laboratory-review-her2-and-er-early-breast-cancer-altto-trial-big-2-06ncctg-n063d 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/high-concordance-protein-ihc-gene-fish-her2-only-and-microarray-readout-targetprint-er-pgr-and-her2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/high-concordance-protein-ihc-gene-fish-her2-only-and-microarray-readout-targetprint-er-pgr-and-her2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/high-concordance-protein-ihc-gene-fish-her2-only-and-microarray-readout-targetprint-er-pgr-and-her2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/why-your-preferred-targeted-drugs-may-become-unaffordable 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/why-your-preferred-targeted-drugs-may-become-unaffordable 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/why-your-preferred-targeted-drugs-may-become-unaffordable 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/eso-esmo-2nd-international-consensus-guidelines-advanced-breast-cancer-abc2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/eso-esmo-2nd-international-consensus-guidelines-advanced-breast-cancer-abc2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/eso-esmo-2nd-international-consensus-guidelines-advanced-breast-cancer-abc2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/eso-esmo-2nd-international-consensus-guidelines-advanced-breast-cancer-abc2-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/eso-esmo-2nd-international-consensus-guidelines-advanced-breast-cancer-abc2-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/eso-esmo-2nd-international-consensus-guidelines-advanced-breast-cancer-abc2-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/words-matter-distinguishing-personalized-medicine-and-biologically-personalized-therapeutics 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/words-matter-distinguishing-personalized-medicine-and-biologically-personalized-therapeutics 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/words-matter-distinguishing-personalized-medicine-and-biologically-personalized-therapeutics 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/current-and-future-role-medical-oncologist-professional-care-cancer-patients-position-paper 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/current-and-future-role-medical-oncologist-professional-care-cancer-patients-position-paper 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/current-and-future-role-medical-oncologist-professional-care-cancer-patients-position-paper 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/incidence-and-time-course-everolimus-related-adverse-events-postmenopausal-women-hormone-receptor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/incidence-and-time-course-everolimus-related-adverse-events-postmenopausal-women-hormone-receptor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/incidence-and-time-course-everolimus-related-adverse-events-postmenopausal-women-hormone-receptor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pathological-complete-response-after-neoadjuvant-chemotherapy-independent-predictive-factor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pathological-complete-response-after-neoadjuvant-chemotherapy-independent-predictive-factor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pathological-complete-response-after-neoadjuvant-chemotherapy-independent-predictive-factor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pathological-complete-response-and-long-term-clinical-benefit-breast-cancer-ctneobc-pooled-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pathological-complete-response-and-long-term-clinical-benefit-breast-cancer-ctneobc-pooled-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pathological-complete-response-and-long-term-clinical-benefit-breast-cancer-ctneobc-pooled-analysis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/delivering-precision-medicine-oncology-today-and-future-promise-and-challenges-personalised-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/delivering-precision-medicine-oncology-today-and-future-promise-and-challenges-personalised-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/delivering-precision-medicine-oncology-today-and-future-promise-and-challenges-personalised-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/neoadjuvant-therapy-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/neoadjuvant-therapy-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/neoadjuvant-therapy-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/maastricht-delphi-consensus-event-definitions-classification-recurrence-breast-cancer-research 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/maastricht-delphi-consensus-event-definitions-classification-recurrence-breast-cancer-research 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/maastricht-delphi-consensus-event-definitions-classification-recurrence-breast-cancer-research 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/understanding-factors-associated-surgical-management-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/understanding-factors-associated-surgical-management-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/understanding-factors-associated-surgical-management-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/locoregional-treatment-breast-cancer-during-pregnancy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/locoregional-treatment-breast-cancer-during-pregnancy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/locoregional-treatment-breast-cancer-during-pregnancy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tumour-associated-osteomalacia-and-hypoglycaemia-patient-prostate-cancer-klotho-involved 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tumour-associated-osteomalacia-and-hypoglycaemia-patient-prostate-cancer-klotho-involved 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tumour-associated-osteomalacia-and-hypoglycaemia-patient-prostate-cancer-klotho-involved 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/five-fraction-gamma-knife-radiosurgery-using-extend-relocatable-system-benign-neoplasms-close-optic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/five-fraction-gamma-knife-radiosurgery-using-extend-relocatable-system-benign-neoplasms-close-optic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/five-fraction-gamma-knife-radiosurgery-using-extend-relocatable-system-benign-neoplasms-close-optic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/transfer-clinically-relevant-gene-expression-signatures-breast-cancer-affymetrix-microarray 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/transfer-clinically-relevant-gene-expression-signatures-breast-cancer-affymetrix-microarray 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/transfer-clinically-relevant-gene-expression-signatures-breast-cancer-affymetrix-microarray 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/factors-associated-continuum-care-hiv-infected-patients-belgium 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/factors-associated-continuum-care-hiv-infected-patients-belgium 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/factors-associated-continuum-care-hiv-infected-patients-belgium 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/hiv-transmission-through-breastfeeding-still-possible-developed-countries 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/hiv-transmission-through-breastfeeding-still-possible-developed-countries 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/hiv-transmission-through-breastfeeding-still-possible-developed-countries 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/both-igg-and-igm-anti-beta2-glycoprotein-i-antibodies-assays-are-clinically-useful-antiphospholipid 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/both-igg-and-igm-anti-beta2-glycoprotein-i-antibodies-assays-are-clinically-useful-antiphospholipid 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/both-igg-and-igm-anti-beta2-glycoprotein-i-antibodies-assays-are-clinically-useful-antiphospholipid 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/evaluation-3-rapid-influenza-diagnostic-tests-during-2012-2013-epidemic-influences-subtype-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-3-rapid-influenza-diagnostic-tests-during-2012-2013-epidemic-influences-subtype-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-3-rapid-influenza-diagnostic-tests-during-2012-2013-epidemic-influences-subtype-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/treatment-small-cell-lung-cancer-limited-disease-guidelines-clinical-practice-made-european-lung 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/treatment-small-cell-lung-cancer-limited-disease-guidelines-clinical-practice-made-european-lung 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/treatment-small-cell-lung-cancer-limited-disease-guidelines-clinical-practice-made-european-lung 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/impact-neoadjuvant-chemoradiotherapy-postoperative-outcomes-after-esophageal-cancer-resection 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-neoadjuvant-chemoradiotherapy-postoperative-outcomes-after-esophageal-cancer-resection 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-neoadjuvant-chemoradiotherapy-postoperative-outcomes-after-esophageal-cancer-resection 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-single-knot-running-vesicourethral-anastomosis-10-years-after-its-introduction-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-single-knot-running-vesicourethral-anastomosis-10-years-after-its-introduction-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-single-knot-running-vesicourethral-anastomosis-10-years-after-its-introduction-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tribute-professor-jacques-henry1921-2014 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tribute-professor-jacques-henry1921-2014 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tribute-professor-jacques-henry1921-2014 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/forty-years-progress-therapeutic-management-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/forty-years-progress-therapeutic-management-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/forty-years-progress-therapeutic-management-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/radiotherapy-indications-non-malignant-diseases-2014 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/radiotherapy-indications-non-malignant-diseases-2014 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/radiotherapy-indications-non-malignant-diseases-2014 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/intensity-modulated-radiation-therapy-non-small-cell-lung-cancers 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/intensity-modulated-radiation-therapy-non-small-cell-lung-cancers 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/intensity-modulated-radiation-therapy-non-small-cell-lung-cancers 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/harmonization-evaluation-tumor-infiltrating-lymphocytes-tils-breast-cancer-recommendations 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/harmonization-evaluation-tumor-infiltrating-lymphocytes-tils-breast-cancer-recommendations 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/harmonization-evaluation-tumor-infiltrating-lymphocytes-tils-breast-cancer-recommendations 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/deciphering-clonality-aneuploid-tumors-using-snp-array-and-sequencing-data 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/deciphering-clonality-aneuploid-tumors-using-snp-array-and-sequencing-data 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/deciphering-clonality-aneuploid-tumors-using-snp-array-and-sequencing-data 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/differentiation-molecular-subtypes-breast-cancer-important-staging-local-and-systemic-therapy-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/differentiation-molecular-subtypes-breast-cancer-important-staging-local-and-systemic-therapy-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/differentiation-molecular-subtypes-breast-cancer-important-staging-local-and-systemic-therapy-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/pik3ca-mutations-are-associated-lower-rates-pathologic-complete-response-anti-human-epidermal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/pik3ca-mutations-are-associated-lower-rates-pathologic-complete-response-anti-human-epidermal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/pik3ca-mutations-are-associated-lower-rates-pathologic-complete-response-anti-human-epidermal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/new-strategies-breast-cancer-significance-molecular-subtypes-systemic-adjuvant-treatment-small 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/new-strategies-breast-cancer-significance-molecular-subtypes-systemic-adjuvant-treatment-small 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/new-strategies-breast-cancer-significance-molecular-subtypes-systemic-adjuvant-treatment-small 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/aurora-initiative-metastatic-breast-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/aurora-initiative-metastatic-breast-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/aurora-initiative-metastatic-breast-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-resectable-non-small-cell-lung-cancer-guidelines-clinical-practice-made-european-lung 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-resectable-non-small-cell-lung-cancer-guidelines-clinical-practice-made-european-lung 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-resectable-non-small-cell-lung-cancer-guidelines-clinical-practice-made-european-lung 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breaking-bad-news-oncology-belgian-experience 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breaking-bad-news-oncology-belgian-experience 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breaking-bad-news-oncology-belgian-experience 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/anxiety-first-radiotherapy-session-non-metastatic-breast-cancer-key-communication-and-communication 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/anxiety-first-radiotherapy-session-non-metastatic-breast-cancer-key-communication-and-communication 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/anxiety-first-radiotherapy-session-non-metastatic-breast-cancer-key-communication-and-communication 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-unresectable-non-metastatic-non-small-cell-lung-cancer-guidelines-clinical-practice-made 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-unresectable-non-metastatic-non-small-cell-lung-cancer-guidelines-clinical-practice-made 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-unresectable-non-metastatic-non-small-cell-lung-cancer-guidelines-clinical-practice-made 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-extensive-disease-small-cell-lung-cancer-guidelines-clinical-practice-made-european-lung 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-extensive-disease-small-cell-lung-cancer-guidelines-clinical-practice-made-european-lung 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-extensive-disease-small-cell-lung-cancer-guidelines-clinical-practice-made-european-lung 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/everolimus-plus-exemestane-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/everolimus-plus-exemestane-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/everolimus-plus-exemestane-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/strategies-empirical-management-infection-cancer-patients-emphasis-emergence-resistant-gram 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/strategies-empirical-management-infection-cancer-patients-emphasis-emergence-resistant-gram 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/strategies-empirical-management-infection-cancer-patients-emphasis-emergence-resistant-gram 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/guidelines-time-event-end-point-definitions-trials-pancreatic-cancer-results-datecan-initiative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/guidelines-time-event-end-point-definitions-trials-pancreatic-cancer-results-datecan-initiative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/guidelines-time-event-end-point-definitions-trials-pancreatic-cancer-results-datecan-initiative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/surgical-strategy-abnormally-increased-fluorine-18-fluorodeoxyglucose-uptake-asymptomatic-lower 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/surgical-strategy-abnormally-increased-fluorine-18-fluorodeoxyglucose-uptake-asymptomatic-lower 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/surgical-strategy-abnormally-increased-fluorine-18-fluorodeoxyglucose-uptake-asymptomatic-lower 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/pioneering-quality-assessment-european-cancer-centers-data-analysis-organization-european-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pioneering-quality-assessment-european-cancer-centers-data-analysis-organization-european-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pioneering-quality-assessment-european-cancer-centers-data-analysis-organization-european-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/menopausal-hormone-therapy-use-17-european-countries-during-last-decade 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/menopausal-hormone-therapy-use-17-european-countries-during-last-decade 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/menopausal-hormone-therapy-use-17-european-countries-during-last-decade 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/lapatinib-trastuzumab-her2-positive-early-breast-cancer-neoaltto-survival-outcomes-randomised-open 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lapatinib-trastuzumab-her2-positive-early-breast-cancer-neoaltto-survival-outcomes-randomised-open 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lapatinib-trastuzumab-her2-positive-early-breast-cancer-neoaltto-survival-outcomes-randomised-open 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/update-parp-inhibitors-moving-adjuvant-setting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/update-parp-inhibitors-moving-adjuvant-setting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/update-parp-inhibitors-moving-adjuvant-setting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/reply-c-fontanella-et-al 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reply-c-fontanella-et-al 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reply-c-fontanella-et-al 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/circadian-and-circannual-variations-cord-blood-hematopoietic-cell-composition 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/circadian-and-circannual-variations-cord-blood-hematopoietic-cell-composition 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/circadian-and-circannual-variations-cord-blood-hematopoietic-cell-composition 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/bone-marrow-mesenchymal-stromal-cells-induce-proliferative-cytokinic-and-molecular-changes-during-t 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/bone-marrow-mesenchymal-stromal-cells-induce-proliferative-cytokinic-and-molecular-changes-during-t 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/bone-marrow-mesenchymal-stromal-cells-induce-proliferative-cytokinic-and-molecular-changes-during-t 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/immune-impairments-multiple-myeloma-bone-marrow-mesenchymal-stromal-cells 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immune-impairments-multiple-myeloma-bone-marrow-mesenchymal-stromal-cells 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immune-impairments-multiple-myeloma-bone-marrow-mesenchymal-stromal-cells 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/myelofibrosis-patients-belgium-disease-characteristics 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/myelofibrosis-patients-belgium-disease-characteristics 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/myelofibrosis-patients-belgium-disease-characteristics 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/guidelines-clinical-practice-made-european-lung-cancer-working-party-updates 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/guidelines-clinical-practice-made-european-lung-cancer-working-party-updates 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/guidelines-clinical-practice-made-european-lung-cancer-working-party-updates 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-resectable-non-small-cell-lung-cancer-guidelines-clinical-practice-made-european-lung-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-resectable-non-small-cell-lung-cancer-guidelines-clinical-practice-made-european-lung-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-resectable-non-small-cell-lung-cancer-guidelines-clinical-practice-made-european-lung-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/plasma-circulating-tumor-dna-alternative-metastatic-biopsies-mutational-analysis-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/plasma-circulating-tumor-dna-alternative-metastatic-biopsies-mutational-analysis-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/plasma-circulating-tumor-dna-alternative-metastatic-biopsies-mutational-analysis-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/phase-ii-trial-evaluating-efficacy-sorafenib-bay-43-9006-and-correlating-early-fdg-pet-ct-response 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/phase-ii-trial-evaluating-efficacy-sorafenib-bay-43-9006-and-correlating-early-fdg-pet-ct-response 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/phase-ii-trial-evaluating-efficacy-sorafenib-bay-43-9006-and-correlating-early-fdg-pet-ct-response 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/efficacy-eribulin-women-metastatic-breast-cancer-pooled-analysis-two-phase-3-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/efficacy-eribulin-women-metastatic-breast-cancer-pooled-analysis-two-phase-3-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/efficacy-eribulin-women-metastatic-breast-cancer-pooled-analysis-two-phase-3-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/mirna-expression-anaplastic-thyroid-carcinomas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/mirna-expression-anaplastic-thyroid-carcinomas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/mirna-expression-anaplastic-thyroid-carcinomas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/mirna-expression-may-account-chronic-not-acute-regulation-mrna-expression-human-thyroid-tumor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/mirna-expression-may-account-chronic-not-acute-regulation-mrna-expression-human-thyroid-tumor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/mirna-expression-may-account-chronic-not-acute-regulation-mrna-expression-human-thyroid-tumor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/regulation-dna-methylation-patterns-ck2-mediated-phosphorylation-dnmt3a 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/regulation-dna-methylation-patterns-ck2-mediated-phosphorylation-dnmt3a 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/regulation-dna-methylation-patterns-ck2-mediated-phosphorylation-dnmt3a 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/treatment-cognitive-impairments-oncology-review-longitudinal-controlled-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/treatment-cognitive-impairments-oncology-review-longitudinal-controlled-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/treatment-cognitive-impairments-oncology-review-longitudinal-controlled-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/improving-communication-cancer-pain-management-nursing-randomized-controlled-study-assessing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/improving-communication-cancer-pain-management-nursing-randomized-controlled-study-assessing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/improving-communication-cancer-pain-management-nursing-randomized-controlled-study-assessing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/single-high-intensity-focused-ultrasound-session-whole-gland-primary-treatment-clinically-localized 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/single-high-intensity-focused-ultrasound-session-whole-gland-primary-treatment-clinically-localized 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/single-high-intensity-focused-ultrasound-session-whole-gland-primary-treatment-clinically-localized 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/microrna-profile-human-cd8 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/microrna-profile-human-cd8 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/microrna-profile-human-cd8 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/proliferative-and-phenotypical-characteristics-human-adipose-tissue-derived-stem-cells-comparison 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/proliferative-and-phenotypical-characteristics-human-adipose-tissue-derived-stem-cells-comparison 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/proliferative-and-phenotypical-characteristics-human-adipose-tissue-derived-stem-cells-comparison 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evolving-paradigms-multifocal-breast-cancer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/evolving-paradigms-multifocal-breast-cancer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/evolving-paradigms-multifocal-breast-cancer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/mobile-dna-cancer-extensive-transduction-nonrepetitive-dna-mediated-l1-retrotransposition-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/mobile-dna-cancer-extensive-transduction-nonrepetitive-dna-mediated-l1-retrotransposition-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/mobile-dna-cancer-extensive-transduction-nonrepetitive-dna-mediated-l1-retrotransposition-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/luminal-b-breast-cancer-molecular-characterization-clinical-management-and-future-perspectives 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/luminal-b-breast-cancer-molecular-characterization-clinical-management-and-future-perspectives 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/luminal-b-breast-cancer-molecular-characterization-clinical-management-and-future-perspectives 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/prevalence-and-implications-elderly-inpatients-desire-formal-psychological-help-start-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prevalence-and-implications-elderly-inpatients-desire-formal-psychological-help-start-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prevalence-and-implications-elderly-inpatients-desire-formal-psychological-help-start-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-pharmacokinetics-study-lapatinib-and-tamoxifen-metastatic-breast-cancer-eortc-10053-lapatam 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-pharmacokinetics-study-lapatinib-and-tamoxifen-metastatic-breast-cancer-eortc-10053-lapatam 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-pharmacokinetics-study-lapatinib-and-tamoxifen-metastatic-breast-cancer-eortc-10053-lapatam 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/parathyroidectomy-primary-hyperparathyroidism-retrospective-study-167-patients-experience-jules 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/parathyroidectomy-primary-hyperparathyroidism-retrospective-study-167-patients-experience-jules 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/parathyroidectomy-primary-hyperparathyroidism-retrospective-study-167-patients-experience-jules 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/role-age-dose-limiting-toxicities-dlts-phase-i-dose-escalation-trials 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/role-age-dose-limiting-toxicities-dlts-phase-i-dose-escalation-trials 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/role-age-dose-limiting-toxicities-dlts-phase-i-dose-escalation-trials 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/treatment-options-pregnant-women-ovarian-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/treatment-options-pregnant-women-ovarian-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/treatment-options-pregnant-women-ovarian-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/same-day-subtyping-campylobacter-jejuni-and-c-coli-isolates-using-multiplex-ligation-dependent 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/same-day-subtyping-campylobacter-jejuni-and-c-coli-isolates-using-multiplex-ligation-dependent 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/same-day-subtyping-campylobacter-jejuni-and-c-coli-isolates-using-multiplex-ligation-dependent 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/safety-and-usefulness-cryopreservation-ovarian-tissue-preserve-fertility-12-year-retrospective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/safety-and-usefulness-cryopreservation-ovarian-tissue-preserve-fertility-12-year-retrospective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/safety-and-usefulness-cryopreservation-ovarian-tissue-preserve-fertility-12-year-retrospective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/early-invasive-cancer-and-partial-intraoperative-electron-radiation-therapy-breast-experience-jules 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/early-invasive-cancer-and-partial-intraoperative-electron-radiation-therapy-breast-experience-jules 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/early-invasive-cancer-and-partial-intraoperative-electron-radiation-therapy-breast-experience-jules 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/multicenter-implementation-geriatric-assessment-belgian-patients-cancer-survey-treating-physicians 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/multicenter-implementation-geriatric-assessment-belgian-patients-cancer-survey-treating-physicians 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/multicenter-implementation-geriatric-assessment-belgian-patients-cancer-survey-treating-physicians 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/early-administration-donor-lymphocyte-infusions-upon-molecular-relapse-after-allogeneic 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/early-administration-donor-lymphocyte-infusions-upon-molecular-relapse-after-allogeneic 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/early-administration-donor-lymphocyte-infusions-upon-molecular-relapse-after-allogeneic 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/treatment-climacteric-symptoms-breast-cancer-patients-retrospective-study-medication-databank 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/treatment-climacteric-symptoms-breast-cancer-patients-retrospective-study-medication-databank 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/treatment-climacteric-symptoms-breast-cancer-patients-retrospective-study-medication-databank 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/antimicrobial-resistance-urinary-isolates-inpatients-and-outpatients-tertiary-care-hospital-south 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/antimicrobial-resistance-urinary-isolates-inpatients-and-outpatients-tertiary-care-hospital-south 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/antimicrobial-resistance-urinary-isolates-inpatients-and-outpatients-tertiary-care-hospital-south 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/challenges-and-controversies-thoracic-oncology-new-erj-series 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/challenges-and-controversies-thoracic-oncology-new-erj-series 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/challenges-and-controversies-thoracic-oncology-new-erj-series 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/inappropriate-care-european-intensive-care-units-confronting-views-nurses-junior-and-senior 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/inappropriate-care-european-intensive-care-units-confronting-views-nurses-junior-and-senior 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/inappropriate-care-european-intensive-care-units-confronting-views-nurses-junior-and-senior 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/acute-respiratory-distress-syndrome-patients-malignancies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/acute-respiratory-distress-syndrome-patients-malignancies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/acute-respiratory-distress-syndrome-patients-malignancies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/narrative-ethics-field-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/narrative-ethics-field-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/narrative-ethics-field-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/chemotherapy-treatment-patterns-and-neutropenia-management-gastric-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/chemotherapy-treatment-patterns-and-neutropenia-management-gastric-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/chemotherapy-treatment-patterns-and-neutropenia-management-gastric-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/times-crisis-go-liquid 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/times-crisis-go-liquid 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/times-crisis-go-liquid 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pretreatment-dosimetry-hcc-radioembolization-90y-glass-microspheres-cannot-be-invalidated-bare 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pretreatment-dosimetry-hcc-radioembolization-90y-glass-microspheres-cannot-be-invalidated-bare 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pretreatment-dosimetry-hcc-radioembolization-90y-glass-microspheres-cannot-be-invalidated-bare 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/biology-breast-cancer-during-pregnancy-using-genomic-profiling 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/biology-breast-cancer-during-pregnancy-using-genomic-profiling 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/biology-breast-cancer-during-pregnancy-using-genomic-profiling 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/information-perception-wishes-and-satisfaction-ambulatory-cancer-patients-under-active-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/information-perception-wishes-and-satisfaction-ambulatory-cancer-patients-under-active-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/information-perception-wishes-and-satisfaction-ambulatory-cancer-patients-under-active-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/trastuzumab-associated-cardiac-events-8-years-median-follow-herceptin-adjuvant-trial-big-1-01 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/trastuzumab-associated-cardiac-events-8-years-median-follow-herceptin-adjuvant-trial-big-1-01 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/trastuzumab-associated-cardiac-events-8-years-median-follow-herceptin-adjuvant-trial-big-1-01 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cardiotoxicity-systemic-agents-used-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cardiotoxicity-systemic-agents-used-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cardiotoxicity-systemic-agents-used-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/isolation-adipose-derived-stromal-cells-without-enzymatic-treatment-expansion-phenotypical-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/isolation-adipose-derived-stromal-cells-without-enzymatic-treatment-expansion-phenotypical-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/isolation-adipose-derived-stromal-cells-without-enzymatic-treatment-expansion-phenotypical-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/correlating-tumor-metabolic-progression-index-measured-serial-fdg-pet-ct-apparent-diffusion 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/correlating-tumor-metabolic-progression-index-measured-serial-fdg-pet-ct-apparent-diffusion 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/correlating-tumor-metabolic-progression-index-measured-serial-fdg-pet-ct-apparent-diffusion 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/eribulin-mesylate-management-metastatic-breast-cancer-and-other-solid-cancers-drug-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/eribulin-mesylate-management-metastatic-breast-cancer-and-other-solid-cancers-drug-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/eribulin-mesylate-management-metastatic-breast-cancer-and-other-solid-cancers-drug-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/detection-herpesviridae-whole-blood-multiplex-pcr-dna-microarray-after-hematopoietic-stem-cell 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/detection-herpesviridae-whole-blood-multiplex-pcr-dna-microarray-after-hematopoietic-stem-cell 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/detection-herpesviridae-whole-blood-multiplex-pcr-dna-microarray-after-hematopoietic-stem-cell 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/vestibular-disorders-euthyroid-patients-hashimoto-s-thyroiditis-role-thyroid-autoimmunity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/vestibular-disorders-euthyroid-patients-hashimoto-s-thyroiditis-role-thyroid-autoimmunity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/vestibular-disorders-euthyroid-patients-hashimoto-s-thyroiditis-role-thyroid-autoimmunity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/first-international-consensus-guidelines-breast-cancer-young-women-bcy1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/first-international-consensus-guidelines-breast-cancer-young-women-bcy1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/first-international-consensus-guidelines-breast-cancer-young-women-bcy1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/identification-zeb2-mitf-zeb1-transcriptional-network-controls-melanogenesis-and-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/identification-zeb2-mitf-zeb1-transcriptional-network-controls-melanogenesis-and-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/identification-zeb2-mitf-zeb1-transcriptional-network-controls-melanogenesis-and-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/international-study-inter-reader-variability-circulating-tumor-cells-breast-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/international-study-inter-reader-variability-circulating-tumor-cells-breast-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/international-study-inter-reader-variability-circulating-tumor-cells-breast-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/anxiety-and-its-time-courses-during-radiotherapy-non-metastatic-breast-cancer-longitudinal-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/anxiety-and-its-time-courses-during-radiotherapy-non-metastatic-breast-cancer-longitudinal-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/anxiety-and-its-time-courses-during-radiotherapy-non-metastatic-breast-cancer-longitudinal-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-dpyd-mutations-and-capecitabine-related-ileitis-description-two-cases-and-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-dpyd-mutations-and-capecitabine-related-ileitis-description-two-cases-and-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-dpyd-mutations-and-capecitabine-related-ileitis-description-two-cases-and-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/downregulation-microrna-24-and-181-parallels-upregulation-ifn-secreted-activated-human-cd4 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/downregulation-microrna-24-and-181-parallels-upregulation-ifn-secreted-activated-human-cd4 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/downregulation-microrna-24-and-181-parallels-upregulation-ifn-secreted-activated-human-cd4 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/processed-pseudogenes-acquired-somatically-during-cancer-development 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/processed-pseudogenes-acquired-somatically-during-cancer-development 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/processed-pseudogenes-acquired-somatically-during-cancer-development 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-iia-nonrandomized-study-radium-223-dichloride-advanced-breast-cancer-patients-bone-dominant 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-iia-nonrandomized-study-radium-223-dichloride-advanced-breast-cancer-patients-bone-dominant 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-iia-nonrandomized-study-radium-223-dichloride-advanced-breast-cancer-patients-bone-dominant 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/use-adjuvant-chemotherapy-ct-and-radiotherapy-rt-incompletely-resected-r1-early-stage-non-small 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/use-adjuvant-chemotherapy-ct-and-radiotherapy-rt-incompletely-resected-r1-early-stage-non-small 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/use-adjuvant-chemotherapy-ct-and-radiotherapy-rt-incompletely-resected-r1-early-stage-non-small 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prognostic-predictive-abilities-and-concordance-bcl2-and-tp53-protein-expression-primary-breast 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-predictive-abilities-and-concordance-bcl2-and-tp53-protein-expression-primary-breast 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-predictive-abilities-and-concordance-bcl2-and-tp53-protein-expression-primary-breast 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/small-cell-lung-cancer-what-are-treatment-results-routine-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/small-cell-lung-cancer-what-are-treatment-results-routine-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/small-cell-lung-cancer-what-are-treatment-results-routine-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-tumor-sequencing-use-anticancer-drugs 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-tumor-sequencing-use-anticancer-drugs 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-tumor-sequencing-use-anticancer-drugs 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/neurofibromatosis-type-i-breast-cancer-not-only-women 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/neurofibromatosis-type-i-breast-cancer-not-only-women 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/neurofibromatosis-type-i-breast-cancer-not-only-women 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/myofibroblastoma-breast-smooth-muscle-differentiation-showing-deletion-13q14-region-report-case 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/myofibroblastoma-breast-smooth-muscle-differentiation-showing-deletion-13q14-region-report-case 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/myofibroblastoma-breast-smooth-muscle-differentiation-showing-deletion-13q14-region-report-case 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/adequate-iron-chelation-therapy-least-six-months-improves-survival-transfusion-dependent-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/adequate-iron-chelation-therapy-least-six-months-improves-survival-transfusion-dependent-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/adequate-iron-chelation-therapy-least-six-months-improves-survival-transfusion-dependent-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/fourteenth-annual-meeting-complications-and-emergencies-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/fourteenth-annual-meeting-complications-and-emergencies-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/fourteenth-annual-meeting-complications-and-emergencies-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/european-respiratory-society-plans-its-future-2013-2018-strategic-plan 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/european-respiratory-society-plans-its-future-2013-2018-strategic-plan 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/european-respiratory-society-plans-its-future-2013-2018-strategic-plan 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/european-initiative-quality-management-lung-cancer-care 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/european-initiative-quality-management-lung-cancer-care 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/european-initiative-quality-management-lung-cancer-care 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/primary-zonal-high-intensity-focused-ultrasound-prostate-cancer-results-prospective-phase-iia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/primary-zonal-high-intensity-focused-ultrasound-prostate-cancer-results-prospective-phase-iia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/primary-zonal-high-intensity-focused-ultrasound-prostate-cancer-results-prospective-phase-iia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/bosutinib-combination-aromatase-inhibitor-exemestane-phase-ii-trial-postmenopausal-women-previously 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bosutinib-combination-aromatase-inhibitor-exemestane-phase-ii-trial-postmenopausal-women-previously 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bosutinib-combination-aromatase-inhibitor-exemestane-phase-ii-trial-postmenopausal-women-previously 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/bosutinib-combination-aromatase-inhibitor-letrozole-phase-ii-trial-postmenopausal-women-evaluating 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bosutinib-combination-aromatase-inhibitor-letrozole-phase-ii-trial-postmenopausal-women-evaluating 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bosutinib-combination-aromatase-inhibitor-letrozole-phase-ii-trial-postmenopausal-women-evaluating 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/human-skin-derived-precursor-cells-are-poorly-immunogenic-and-modulate-allogeneic-immune-response 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/human-skin-derived-precursor-cells-are-poorly-immunogenic-and-modulate-allogeneic-immune-response 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/human-skin-derived-precursor-cells-are-poorly-immunogenic-and-modulate-allogeneic-immune-response 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cytology-undetermined-diagnoses-and-unsatisfactory-samples 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cytology-undetermined-diagnoses-and-unsatisfactory-samples 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cytology-undetermined-diagnoses-and-unsatisfactory-samples 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tumor-infiltrating-lymphocytes-prognostic-and-predictive-trastuzumab-benefit-early-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tumor-infiltrating-lymphocytes-prognostic-and-predictive-trastuzumab-benefit-early-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tumor-infiltrating-lymphocytes-prognostic-and-predictive-trastuzumab-benefit-early-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/controversial-issues-early-stage-breast-cancer-global-collaborative-survey-supported-european 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/controversial-issues-early-stage-breast-cancer-global-collaborative-survey-supported-european 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/controversial-issues-early-stage-breast-cancer-global-collaborative-survey-supported-european 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/factors-affecting-surgical-management-following-neoadjuvant-therapy-patients-primary-her2-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/factors-affecting-surgical-management-following-neoadjuvant-therapy-patients-primary-her2-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/factors-affecting-surgical-management-following-neoadjuvant-therapy-patients-primary-her2-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/oncological-intensive-care-2012-year-s-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/oncological-intensive-care-2012-year-s-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/oncological-intensive-care-2012-year-s-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/contribution-identification-occupational-exposure-thoracic-oncology-belgian-experience 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/contribution-identification-occupational-exposure-thoracic-oncology-belgian-experience 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/contribution-identification-occupational-exposure-thoracic-oncology-belgian-experience 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/updates-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/updates-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/updates-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/anticancer-drug-development-moving-away-old-habits 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/anticancer-drug-development-moving-away-old-habits 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/anticancer-drug-development-moving-away-old-habits 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/randomized-controlled-phase-ii-trial-novel-composition-paclitaxel-embedded-neutral-and-cationic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/randomized-controlled-phase-ii-trial-novel-composition-paclitaxel-embedded-neutral-and-cationic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/randomized-controlled-phase-ii-trial-novel-composition-paclitaxel-embedded-neutral-and-cationic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prominent-role-cyclic-adenosine-monophosphate-signalling-pathway-sensitivity-wtbrafwtnras-melanoma 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/prominent-role-cyclic-adenosine-monophosphate-signalling-pathway-sensitivity-wtbrafwtnras-melanoma 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/prominent-role-cyclic-adenosine-monophosphate-signalling-pathway-sensitivity-wtbrafwtnras-melanoma 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/presence-and-analysis-plasmids-human-and-animal-associated-arcobacter-species 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/presence-and-analysis-plasmids-human-and-animal-associated-arcobacter-species 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/presence-and-analysis-plasmids-human-and-animal-associated-arcobacter-species 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/tumor-texture-analysis-18f-fdg-pet-relationships-between-texture-parameters-histogram-indices 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tumor-texture-analysis-18f-fdg-pet-relationships-between-texture-parameters-histogram-indices 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tumor-texture-analysis-18f-fdg-pet-relationships-between-texture-parameters-histogram-indices 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/her4-and-its-cytoplasmic-isoforms-are-associated-progression-free-survival-malignant-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/her4-and-its-cytoplasmic-isoforms-are-associated-progression-free-survival-malignant-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/her4-and-its-cytoplasmic-isoforms-are-associated-progression-free-survival-malignant-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/long-term-evaluation-oncologic-and-functional-outcomes-after-laparoscopic-open-assisted-radical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/long-term-evaluation-oncologic-and-functional-outcomes-after-laparoscopic-open-assisted-radical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/long-term-evaluation-oncologic-and-functional-outcomes-after-laparoscopic-open-assisted-radical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/infrared-imaging-breast-cancer-automated-tissue-component-recognition-and-spectral-characterization 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/infrared-imaging-breast-cancer-automated-tissue-component-recognition-and-spectral-characterization 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/infrared-imaging-breast-cancer-automated-tissue-component-recognition-and-spectral-characterization 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/landscape-medical-oncology-europe-2020 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/landscape-medical-oncology-europe-2020 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/landscape-medical-oncology-europe-2020 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/tnm-classification-and-clinicopathological-factors-what-helpful-adjuvant-chemotherapy-decision 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tnm-classification-and-clinicopathological-factors-what-helpful-adjuvant-chemotherapy-decision 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tnm-classification-and-clinicopathological-factors-what-helpful-adjuvant-chemotherapy-decision 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/molecular-biology-medical-oncology-diagnosis-prognosis-and-precision-medicine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/molecular-biology-medical-oncology-diagnosis-prognosis-and-precision-medicine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/molecular-biology-medical-oncology-diagnosis-prognosis-and-precision-medicine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-young-women-special-issue 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-young-women-special-issue 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-young-women-special-issue 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/3d-versus-2d-systematic-transrectal-ultrasound-guided-prostate-biopsy-higher-cancer-detection-rate 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/3d-versus-2d-systematic-transrectal-ultrasound-guided-prostate-biopsy-higher-cancer-detection-rate 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/3d-versus-2d-systematic-transrectal-ultrasound-guided-prostate-biopsy-higher-cancer-detection-rate 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/live-surgical-education-perspective-surgeons-who-perform-it 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/live-surgical-education-perspective-surgeons-who-perform-it 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/live-surgical-education-perspective-surgeons-who-perform-it 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/bad-behaviors-regarding-research-and-scientific-and-medical-publication 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bad-behaviors-regarding-research-and-scientific-and-medical-publication 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bad-behaviors-regarding-research-and-scientific-and-medical-publication 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/her2-staining-intensity-her2-positive-disease-relationship-fish-amplification-and-clinical-outcome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/her2-staining-intensity-her2-positive-disease-relationship-fish-amplification-and-clinical-outcome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/her2-staining-intensity-her2-positive-disease-relationship-fish-amplification-and-clinical-outcome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/autoimmune-haemolytic-anaemia-patient-treated-capecitabine 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/autoimmune-haemolytic-anaemia-patient-treated-capecitabine 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/autoimmune-haemolytic-anaemia-patient-treated-capecitabine 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/metasin-intra-operative-rt-qpcr-assay-detect-metastatic-breast-cancer-sentinel-lymph-nodes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/metasin-intra-operative-rt-qpcr-assay-detect-metastatic-breast-cancer-sentinel-lymph-nodes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/metasin-intra-operative-rt-qpcr-assay-detect-metastatic-breast-cancer-sentinel-lymph-nodes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/characterization-hepatic-markers-human-wharton-s-jelly-derived-mesenchymal-stem-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/characterization-hepatic-markers-human-wharton-s-jelly-derived-mesenchymal-stem-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/characterization-hepatic-markers-human-wharton-s-jelly-derived-mesenchymal-stem-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/genomic-grade-index-ggi-feasibility-routine-practice-and-impact-treatment-decisions-early-breast 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/genomic-grade-index-ggi-feasibility-routine-practice-and-impact-treatment-decisions-early-breast 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/genomic-grade-index-ggi-feasibility-routine-practice-and-impact-treatment-decisions-early-breast 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/how-long-enough-optimal-timing-anti-her2neu-therapy-adjuvant-setting-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/how-long-enough-optimal-timing-anti-her2neu-therapy-adjuvant-setting-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/how-long-enough-optimal-timing-anti-her2neu-therapy-adjuvant-setting-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/trastuzumab-patients-her2-positive-breast-cancer-delivery-duration-and-combination-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/trastuzumab-patients-her2-positive-breast-cancer-delivery-duration-and-combination-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/trastuzumab-patients-her2-positive-breast-cancer-delivery-duration-and-combination-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/thoracic-oncology-annual-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/thoracic-oncology-annual-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/thoracic-oncology-annual-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/atypical-presentation-bronchial-adenocarcinoma 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/atypical-presentation-bronchial-adenocarcinoma 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/atypical-presentation-bronchial-adenocarcinoma 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/comparison-gene-expression-profiling-strategy-standard-clinical-work-determination-tumour-origin 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/comparison-gene-expression-profiling-strategy-standard-clinical-work-determination-tumour-origin 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/comparison-gene-expression-profiling-strategy-standard-clinical-work-determination-tumour-origin 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/performance-and-abnormal-cell-flagging-comparisons-three-automated-blood-cell-counters-cell-dyn 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/performance-and-abnormal-cell-flagging-comparisons-three-automated-blood-cell-counters-cell-dyn 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/performance-and-abnormal-cell-flagging-comparisons-three-automated-blood-cell-counters-cell-dyn 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/multicenter-harmonization-89zr-petct-performance 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/multicenter-harmonization-89zr-petct-performance 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/multicenter-harmonization-89zr-petct-performance 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/european-lung-corner 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/european-lung-corner 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/european-lung-corner 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/everolimus-plus-exemestane-first-line-therapy-hr-her2-advanced-breast-cancer-bolero-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/everolimus-plus-exemestane-first-line-therapy-hr-her2-advanced-breast-cancer-bolero-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/everolimus-plus-exemestane-first-line-therapy-hr-her2-advanced-breast-cancer-bolero-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/high-dose-cytarabine-induction-treatment-improves-outcome-adult-patients-younger-age-46-years-acute 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/high-dose-cytarabine-induction-treatment-improves-outcome-adult-patients-younger-age-46-years-acute 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/high-dose-cytarabine-induction-treatment-improves-outcome-adult-patients-younger-age-46-years-acute 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/elcwp-phase-iii-trial-comparing-ifosfamide-and-cisplatin-regimens-advanced-nsclc 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/elcwp-phase-iii-trial-comparing-ifosfamide-and-cisplatin-regimens-advanced-nsclc 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/elcwp-phase-iii-trial-comparing-ifosfamide-and-cisplatin-regimens-advanced-nsclc 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/present-and-future-breast-cancer-management-bench-bedside-and-back-positioning-paper-academia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/present-and-future-breast-cancer-management-bench-bedside-and-back-positioning-paper-academia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/present-and-future-breast-cancer-management-bench-bedside-and-back-positioning-paper-academia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-rapid-microbial-identification-directly-positive-blood-cultures-using-matrix-assisted-laser 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-rapid-microbial-identification-directly-positive-blood-cultures-using-matrix-assisted-laser 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-rapid-microbial-identification-directly-positive-blood-cultures-using-matrix-assisted-laser 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/superficial-acral-fibromyxoma-sub-matricial-location-unusual-variant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/superficial-acral-fibromyxoma-sub-matricial-location-unusual-variant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/superficial-acral-fibromyxoma-sub-matricial-location-unusual-variant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/extraskeletal-osteosarcoma-international-rare-cancer-network-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/extraskeletal-osteosarcoma-international-rare-cancer-network-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/extraskeletal-osteosarcoma-international-rare-cancer-network-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/tp53-mutation-correlated-genes-predict-risk-tumor-relapse-and-identify-mps1-potential-therapeutic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tp53-mutation-correlated-genes-predict-risk-tumor-relapse-and-identify-mps1-potential-therapeutic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tp53-mutation-correlated-genes-predict-risk-tumor-relapse-and-identify-mps1-potential-therapeutic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/fine-needle-aspiration-and-medullary-thyroid-carcinoma-risk-inadequate-preoperative-evaluation-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/fine-needle-aspiration-and-medullary-thyroid-carcinoma-risk-inadequate-preoperative-evaluation-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/fine-needle-aspiration-and-medullary-thyroid-carcinoma-risk-inadequate-preoperative-evaluation-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cancer-pregnancy-and-fertility-esmo-clinical-practice-guidelines-diagnosis-treatment-and-follow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cancer-pregnancy-and-fertility-esmo-clinical-practice-guidelines-diagnosis-treatment-and-follow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cancer-pregnancy-and-fertility-esmo-clinical-practice-guidelines-diagnosis-treatment-and-follow 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-arising-young-age-do-we-need-define-cut 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-arising-young-age-do-we-need-define-cut 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-arising-young-age-do-we-need-define-cut 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/subtype-determination-blastocystis-isolates-matrix-assisted-laser-desorptionionisation-time-flight 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/subtype-determination-blastocystis-isolates-matrix-assisted-laser-desorptionionisation-time-flight 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/subtype-determination-blastocystis-isolates-matrix-assisted-laser-desorptionionisation-time-flight 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/feasibility-matrix-assisted-laser-desorptionionisation-time-flight-mass-spectrometry-maldi-tof-ms 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/feasibility-matrix-assisted-laser-desorptionionisation-time-flight-mass-spectrometry-maldi-tof-ms 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/feasibility-matrix-assisted-laser-desorptionionisation-time-flight-mass-spectrometry-maldi-tof-ms 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/ethnobotanical-survey-medicinal-plants-used-rwanda-voluntary-depigmentation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/ethnobotanical-survey-medicinal-plants-used-rwanda-voluntary-depigmentation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/ethnobotanical-survey-medicinal-plants-used-rwanda-voluntary-depigmentation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/reply-letter-re-general-theory-predictive-dosimetry-yttrium-90-radioembolization-sites-other-liver 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reply-letter-re-general-theory-predictive-dosimetry-yttrium-90-radioembolization-sites-other-liver 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reply-letter-re-general-theory-predictive-dosimetry-yttrium-90-radioembolization-sites-other-liver 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pitfalls-monoclonal-gammopathy 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/pitfalls-monoclonal-gammopathy 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/pitfalls-monoclonal-gammopathy 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/tumor-infiltrating-follicular-helper-t-cells-new-kids-block 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tumor-infiltrating-follicular-helper-t-cells-new-kids-block 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tumor-infiltrating-follicular-helper-t-cells-new-kids-block 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/focus-screening-prostate-cancer-psa 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/focus-screening-prostate-cancer-psa 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/focus-screening-prostate-cancer-psa 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/thoracic-oncology-14th-annual-meeting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/thoracic-oncology-14th-annual-meeting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/thoracic-oncology-14th-annual-meeting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/studies-lung-cancer-management-routine-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/studies-lung-cancer-management-routine-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/studies-lung-cancer-management-routine-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pulmonologists-and-lung-cancer-pivotal-role-multidisciplinary-approach 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pulmonologists-and-lung-cancer-pivotal-role-multidisciplinary-approach 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pulmonologists-and-lung-cancer-pivotal-role-multidisciplinary-approach 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/effect-communication-skills-training-residents-physiological-arousal-breaking-bad-news-simulated 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/effect-communication-skills-training-residents-physiological-arousal-breaking-bad-news-simulated 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/effect-communication-skills-training-residents-physiological-arousal-breaking-bad-news-simulated 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/it-possible-improve-breaking-bad-news-skills-residents-when-relative-present-randomised-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/it-possible-improve-breaking-bad-news-skills-residents-when-relative-present-randomised-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/it-possible-improve-breaking-bad-news-skills-residents-when-relative-present-randomised-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/proliferation-and-estrogen-signaling-can-distinguish-patients-risk-early-versus-late-relapse-among 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/proliferation-and-estrogen-signaling-can-distinguish-patients-risk-early-versus-late-relapse-among 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/proliferation-and-estrogen-signaling-can-distinguish-patients-risk-early-versus-late-relapse-among 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-effect-computer-aided-classification-benign-and-malignant-lesions-reader-performance 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-effect-computer-aided-classification-benign-and-malignant-lesions-reader-performance 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-effect-computer-aided-classification-benign-and-malignant-lesions-reader-performance 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/top2a-protein-quantitative-immunofluorescence-predictor-response-epirubicin-neoadjuvant-treatment 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/top2a-protein-quantitative-immunofluorescence-predictor-response-epirubicin-neoadjuvant-treatment 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/top2a-protein-quantitative-immunofluorescence-predictor-response-epirubicin-neoadjuvant-treatment 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/supportive-care-after-curative-treatment-breast-cancer-survivorship-care-resource-allocations-low 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/supportive-care-after-curative-treatment-breast-cancer-survivorship-care-resource-allocations-low 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/supportive-care-after-curative-treatment-breast-cancer-survivorship-care-resource-allocations-low 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/18f-fdg-petct-early-prediction-response-neoadjuvant-lapatinib-trastuzumab-and-their-combination 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/18f-fdg-petct-early-prediction-response-neoadjuvant-lapatinib-trastuzumab-and-their-combination 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/18f-fdg-petct-early-prediction-response-neoadjuvant-lapatinib-trastuzumab-and-their-combination 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-practice-changing-trials-hera-study-paradigm 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-practice-changing-trials-hera-study-paradigm 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-practice-changing-trials-hera-study-paradigm 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/discrepancies-cancer-incidence-and-mortality-and-its-relationship-health-expenditure-27-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/discrepancies-cancer-incidence-and-mortality-and-its-relationship-health-expenditure-27-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/discrepancies-cancer-incidence-and-mortality-and-its-relationship-health-expenditure-27-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pattern-rash-diarrhea-and-hepatic-toxicities-secondary-lapatinib-and-their-association-age-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pattern-rash-diarrhea-and-hepatic-toxicities-secondary-lapatinib-and-their-association-age-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pattern-rash-diarrhea-and-hepatic-toxicities-secondary-lapatinib-and-their-association-age-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/circulating-tumor-cells-and-response-neoadjuvant-paclitaxel-and-her2-targeted-therapy-sub-study 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/circulating-tumor-cells-and-response-neoadjuvant-paclitaxel-and-her2-targeted-therapy-sub-study 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/circulating-tumor-cells-and-response-neoadjuvant-paclitaxel-and-her2-targeted-therapy-sub-study 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/randomized-study-interferon-2b-versus-no-treatment-consolidation-after-high-dose-therapy-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/randomized-study-interferon-2b-versus-no-treatment-consolidation-after-high-dose-therapy-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/randomized-study-interferon-2b-versus-no-treatment-consolidation-after-high-dose-therapy-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/rational-approach-leucocytosis-adults 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/rational-approach-leucocytosis-adults 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/rational-approach-leucocytosis-adults 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/two-schedules-etirinotecan-pegol-nktr-102-patients-previously-treated-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/two-schedules-etirinotecan-pegol-nktr-102-patients-previously-treated-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/two-schedules-etirinotecan-pegol-nktr-102-patients-previously-treated-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/optimization-campylobacter-growth-conditions-further-identification-matrix-assisted-laser 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/optimization-campylobacter-growth-conditions-further-identification-matrix-assisted-laser 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/optimization-campylobacter-growth-conditions-further-identification-matrix-assisted-laser 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/diagnosis-and-follow-monoclonal-gammopathies-undetermined-significance-information-referring 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/diagnosis-and-follow-monoclonal-gammopathies-undetermined-significance-information-referring 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/diagnosis-and-follow-monoclonal-gammopathies-undetermined-significance-information-referring 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/ability-informal-primary-caregivers-accurately-report-cancer-patients-difficulties 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/ability-informal-primary-caregivers-accurately-report-cancer-patients-difficulties 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/ability-informal-primary-caregivers-accurately-report-cancer-patients-difficulties 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/it-possible-improve-radiotherapy-team-members-communication-skills-randomized-study-assessing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/it-possible-improve-radiotherapy-team-members-communication-skills-randomized-study-assessing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/it-possible-improve-radiotherapy-team-members-communication-skills-randomized-study-assessing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/thoracic-oncology-hermes-syllabus-setting-basis-thoracic-oncology-training-europe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/thoracic-oncology-hermes-syllabus-setting-basis-thoracic-oncology-training-europe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/thoracic-oncology-hermes-syllabus-setting-basis-thoracic-oncology-training-europe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-molecular-biology-techniques-management-newly-diagnosed-chronic-myeloid-leukemia-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-molecular-biology-techniques-management-newly-diagnosed-chronic-myeloid-leukemia-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-molecular-biology-techniques-management-newly-diagnosed-chronic-myeloid-leukemia-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/reply-z-blumenfeld-et-al 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/reply-z-blumenfeld-et-al 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/reply-z-blumenfeld-et-al 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/identification-microrna-based-signatures-response-and-survival-non-small-cell-lung-cancer-treated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/identification-microrna-based-signatures-response-and-survival-non-small-cell-lung-cancer-treated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/identification-microrna-based-signatures-response-and-survival-non-small-cell-lung-cancer-treated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-trial-combining-temozolomide-plus-lapatinib-treatment-brain-metastases-patients-her2 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-trial-combining-temozolomide-plus-lapatinib-treatment-brain-metastases-patients-her2 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-trial-combining-temozolomide-plus-lapatinib-treatment-brain-metastases-patients-her2 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/quality-assurance-head-and-neck-surgical-oncology-eortc-24954-trial-larynx-preservation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/quality-assurance-head-and-neck-surgical-oncology-eortc-24954-trial-larynx-preservation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/quality-assurance-head-and-neck-surgical-oncology-eortc-24954-trial-larynx-preservation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/esut-expert-group-laparoscopy-proposes-uniform-terminology-during-radical-prostatectomy-we-need 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/esut-expert-group-laparoscopy-proposes-uniform-terminology-during-radical-prostatectomy-we-need 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/esut-expert-group-laparoscopy-proposes-uniform-terminology-during-radical-prostatectomy-we-need 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/combination-gemcitabine-and-cetuximab-patients-advanced-cholangiocarcinoma-phase-ii-study-belgian 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/combination-gemcitabine-and-cetuximab-patients-advanced-cholangiocarcinoma-phase-ii-study-belgian 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/combination-gemcitabine-and-cetuximab-patients-advanced-cholangiocarcinoma-phase-ii-study-belgian 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/official-american-thoracic-societyeuropean-respiratory-society-statement-role-pulmonologist 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/official-american-thoracic-societyeuropean-respiratory-society-statement-role-pulmonologist 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/official-american-thoracic-societyeuropean-respiratory-society-statement-role-pulmonologist 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/personalizing-treatment-women-early-breast-cancer-highlights-st-gallen-international-expert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/personalizing-treatment-women-early-breast-cancer-highlights-st-gallen-international-expert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/personalizing-treatment-women-early-breast-cancer-highlights-st-gallen-international-expert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/systematic-review-about-breast-cancer-incidence-relation-hormone-replacement-therapy-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/systematic-review-about-breast-cancer-incidence-relation-hormone-replacement-therapy-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/systematic-review-about-breast-cancer-incidence-relation-hormone-replacement-therapy-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/outcomes-critically-ill-patients-hematologic-malignancies-prospective-multicenter-data-france-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/outcomes-critically-ill-patients-hematologic-malignancies-prospective-multicenter-data-france-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/outcomes-critically-ill-patients-hematologic-malignancies-prospective-multicenter-data-france-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/aetiological-diagnosis-acute-respiratory-failure-critical-care-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/aetiological-diagnosis-acute-respiratory-failure-critical-care-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/aetiological-diagnosis-acute-respiratory-failure-critical-care-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/vivo-production-mesenchymal-stromal-cells-after-injection-autologous-platelet-rich-plasma-activated 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/vivo-production-mesenchymal-stromal-cells-after-injection-autologous-platelet-rich-plasma-activated 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/vivo-production-mesenchymal-stromal-cells-after-injection-autologous-platelet-rich-plasma-activated 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/phase-two-randomised-trial-neratinib-monotherapy-versus-lapatinib-plus-capecitabine-combination 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-two-randomised-trial-neratinib-monotherapy-versus-lapatinib-plus-capecitabine-combination 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-two-randomised-trial-neratinib-monotherapy-versus-lapatinib-plus-capecitabine-combination 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/somatic-mutation-profiling-and-associations-prognosis-and-trastuzumab-benefit-early-breast-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/somatic-mutation-profiling-and-associations-prognosis-and-trastuzumab-benefit-early-breast-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/somatic-mutation-profiling-and-associations-prognosis-and-trastuzumab-benefit-early-breast-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/luminal-breast-cancer-biology-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/luminal-breast-cancer-biology-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/luminal-breast-cancer-biology-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/asthma-control-measurement-using-five-different-questionnaires-prospective-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/asthma-control-measurement-using-five-different-questionnaires-prospective-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/asthma-control-measurement-using-five-different-questionnaires-prospective-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/liquid-based-cytology-breast-pitfalls-unrecognized-specific-liquid-based-cytology-training-proposal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/liquid-based-cytology-breast-pitfalls-unrecognized-specific-liquid-based-cytology-training-proposal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/liquid-based-cytology-breast-pitfalls-unrecognized-specific-liquid-based-cytology-training-proposal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/2-years-versus-1-year-adjuvant-trastuzumab-her2-positive-breast-cancer-hera-open-label-randomised 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/2-years-versus-1-year-adjuvant-trastuzumab-her2-positive-breast-cancer-hera-open-label-randomised 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/2-years-versus-1-year-adjuvant-trastuzumab-her2-positive-breast-cancer-hera-open-label-randomised 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cd4-follicular-helper-t-cell-infiltration-predicts-breast-cancer-survival 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/cd4-follicular-helper-t-cell-infiltration-predicts-breast-cancer-survival 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/cd4-follicular-helper-t-cell-infiltration-predicts-breast-cancer-survival 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/randomized-phase-ii-study-anti-epidermal-growth-factor-receptor-monoclonal-antibody-cetuximab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/randomized-phase-ii-study-anti-epidermal-growth-factor-receptor-monoclonal-antibody-cetuximab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/randomized-phase-ii-study-anti-epidermal-growth-factor-receptor-monoclonal-antibody-cetuximab 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/sequential-use-protein-kinase-inhibitors-potentiates-their-toxicity-melanoma-cells-rationale 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/sequential-use-protein-kinase-inhibitors-potentiates-their-toxicity-melanoma-cells-rationale 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/sequential-use-protein-kinase-inhibitors-potentiates-their-toxicity-melanoma-cells-rationale 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/differentiated-thyroid-carcinoma-defining-new-paradigms-post-operative-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/differentiated-thyroid-carcinoma-defining-new-paradigms-post-operative-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/differentiated-thyroid-carcinoma-defining-new-paradigms-post-operative-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/targeting-rankl-breast-cancer-bone-metastasis-and-beyond 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/targeting-rankl-breast-cancer-bone-metastasis-and-beyond 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/targeting-rankl-breast-cancer-bone-metastasis-and-beyond 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/utility-prognostic-genomic-tests-breast-cancer-practice-impakt-2012-working-group-consensus 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/utility-prognostic-genomic-tests-breast-cancer-practice-impakt-2012-working-group-consensus 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/utility-prognostic-genomic-tests-breast-cancer-practice-impakt-2012-working-group-consensus 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/chemotherapy-targeted-agents-antiemetics-and-growth-factors-human-milk-how-should-we-counsel-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/chemotherapy-targeted-agents-antiemetics-and-growth-factors-human-milk-how-should-we-counsel-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/chemotherapy-targeted-agents-antiemetics-and-growth-factors-human-milk-how-should-we-counsel-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/variations-catheter-related-bloodstream-infections-rates-based-local-practices 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/variations-catheter-related-bloodstream-infections-rates-based-local-practices 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/variations-catheter-related-bloodstream-infections-rates-based-local-practices 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/identification-trichophyton-mentagrophytes-complex-species-using-maldi-tof-mass-spectrometry 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/identification-trichophyton-mentagrophytes-complex-species-using-maldi-tof-mass-spectrometry 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/identification-trichophyton-mentagrophytes-complex-species-using-maldi-tof-mass-spectrometry 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/role-epsilonproteobacteria-children-gastroenteritis 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/role-epsilonproteobacteria-children-gastroenteritis 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/role-epsilonproteobacteria-children-gastroenteritis 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/evaluation-10-serological-assays-diagnosing-mycoplasma-pneumoniae-infection 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-10-serological-assays-diagnosing-mycoplasma-pneumoniae-infection 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-10-serological-assays-diagnosing-mycoplasma-pneumoniae-infection 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/human-papillomavirus-predicts-outcome-following-concomitant-chemoradiotherapy-patients-head-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/human-papillomavirus-predicts-outcome-following-concomitant-chemoradiotherapy-patients-head-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/human-papillomavirus-predicts-outcome-following-concomitant-chemoradiotherapy-patients-head-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/tangential-excision-pigmented-nail-matrix-lesions-responsible-longitudinal-melanonychia-evaluation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tangential-excision-pigmented-nail-matrix-lesions-responsible-longitudinal-melanonychia-evaluation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tangential-excision-pigmented-nail-matrix-lesions-responsible-longitudinal-melanonychia-evaluation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-situ-melanoma-nail-apparatus-functional-surgery-report-11-cases-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-situ-melanoma-nail-apparatus-functional-surgery-report-11-cases-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-situ-melanoma-nail-apparatus-functional-surgery-report-11-cases-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pancreatic-tuberculosis-diagnosed-eus-one-disease-many-faces 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/pancreatic-tuberculosis-diagnosed-eus-one-disease-many-faces 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/pancreatic-tuberculosis-diagnosed-eus-one-disease-many-faces 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/tyrosinase-modulation-five-rwandese-herbal-medicines-traditionally-used-skin-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tyrosinase-modulation-five-rwandese-herbal-medicines-traditionally-used-skin-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tyrosinase-modulation-five-rwandese-herbal-medicines-traditionally-used-skin-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pharmacological-inhibition-macrophage-migration-inhibitory-factor-interferes-proliferation-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/pharmacological-inhibition-macrophage-migration-inhibitory-factor-interferes-proliferation-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/pharmacological-inhibition-macrophage-migration-inhibitory-factor-interferes-proliferation-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/interactions-between-immunity-proliferation-and-molecular-subtype-breast-cancer-prognosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/interactions-between-immunity-proliferation-and-molecular-subtype-breast-cancer-prognosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/interactions-between-immunity-proliferation-and-molecular-subtype-breast-cancer-prognosis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/nonsmall-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/nonsmall-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/nonsmall-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/improved-tolerability-modified-intermittent-treatment-schedule-dasatinib-patients-chronic-myeloid 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/improved-tolerability-modified-intermittent-treatment-schedule-dasatinib-patients-chronic-myeloid 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/improved-tolerability-modified-intermittent-treatment-schedule-dasatinib-patients-chronic-myeloid 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/continuous-sedation-practical-and-ethical-aspects 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/continuous-sedation-practical-and-ethical-aspects 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/continuous-sedation-practical-and-ethical-aspects 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/health-related-quality-life-patients-advanced-breast-cancer-treated-everolimus-plus-exemestane 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/health-related-quality-life-patients-advanced-breast-cancer-treated-everolimus-plus-exemestane 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/health-related-quality-life-patients-advanced-breast-cancer-treated-everolimus-plus-exemestane 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/multinational-association-supportive-care-cancer-mascc-risk-index-score-10-years-use-identifying 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/multinational-association-supportive-care-cancer-mascc-risk-index-score-10-years-use-identifying 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/multinational-association-supportive-care-cancer-mascc-risk-index-score-10-years-use-identifying 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/mascc-neutropenia-infection-and-myelosuppression-study-group-evaluates-recent-new-concepts-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/mascc-neutropenia-infection-and-myelosuppression-study-group-evaluates-recent-new-concepts-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/mascc-neutropenia-infection-and-myelosuppression-study-group-evaluates-recent-new-concepts-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/role-and-interpretation-fluorodeoxyglucose-positron-emission-tomographycomputed-tomography-hiv 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/role-and-interpretation-fluorodeoxyglucose-positron-emission-tomographycomputed-tomography-hiv 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/role-and-interpretation-fluorodeoxyglucose-positron-emission-tomographycomputed-tomography-hiv 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/sustained-viral-suppression-and-higher-cd4-t-cell-count-reduces-risk-persistent-cervical-high-risk 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/sustained-viral-suppression-and-higher-cd4-t-cell-count-reduces-risk-persistent-cervical-high-risk 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/sustained-viral-suppression-and-higher-cd4-t-cell-count-reduces-risk-persistent-cervical-high-risk 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/association-between-sparc-mrna-expression-prognosis-and-response-neoadjuvant-chemotherapy-early 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/association-between-sparc-mrna-expression-prognosis-and-response-neoadjuvant-chemotherapy-early 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/association-between-sparc-mrna-expression-prognosis-and-response-neoadjuvant-chemotherapy-early 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/change-microenvironment-breast-cancer-studied-ftir-imaging 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/change-microenvironment-breast-cancer-studied-ftir-imaging 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/change-microenvironment-breast-cancer-studied-ftir-imaging 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-and-melanoma-cell-line-identification-ftir-imaging-after-formalin-fixation-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-and-melanoma-cell-line-identification-ftir-imaging-after-formalin-fixation-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-and-melanoma-cell-line-identification-ftir-imaging-after-formalin-fixation-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/planning-cancer-control-latin-america-and-caribbean 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/planning-cancer-control-latin-america-and-caribbean 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/planning-cancer-control-latin-america-and-caribbean 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/factors-associated-surgical-management-following-neoadjuvant-therapy-patients-primary-her2-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/factors-associated-surgical-management-following-neoadjuvant-therapy-patients-primary-her2-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/factors-associated-surgical-management-following-neoadjuvant-therapy-patients-primary-her2-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/intrathecal-administration-trastuzumab-treatment-meningeal-carcinomatosis-her2-positive-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/intrathecal-administration-trastuzumab-treatment-meningeal-carcinomatosis-her2-positive-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/intrathecal-administration-trastuzumab-treatment-meningeal-carcinomatosis-her2-positive-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/targeting-pi3kaktmtor-and-rafmekerk-pathways-treatment-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/targeting-pi3kaktmtor-and-rafmekerk-pathways-treatment-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/targeting-pi3kaktmtor-and-rafmekerk-pathways-treatment-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/magnitude-trastuzumab-benefit-patients-her2-positive-invasive-lobular-breast-carcinoma-results-hera 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/magnitude-trastuzumab-benefit-patients-her2-positive-invasive-lobular-breast-carcinoma-results-hera 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/magnitude-trastuzumab-benefit-patients-her2-positive-invasive-lobular-breast-carcinoma-results-hera 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/evidences-early-senescence-multiple-myeloma-bone-marrow-mesenchymal-stromal-cells 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/evidences-early-senescence-multiple-myeloma-bone-marrow-mesenchymal-stromal-cells 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/evidences-early-senescence-multiple-myeloma-bone-marrow-mesenchymal-stromal-cells 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/impact-different-mesenchymal-stromal-cell-types-t-cell-activation-proliferation-and-migration 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-different-mesenchymal-stromal-cell-types-t-cell-activation-proliferation-and-migration 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-different-mesenchymal-stromal-cell-types-t-cell-activation-proliferation-and-migration 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/bravissimo-12-month-results-large-scale-prospective-trial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bravissimo-12-month-results-large-scale-prospective-trial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bravissimo-12-month-results-large-scale-prospective-trial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/slow-growing-lung-cancer-emerging-entity-screening-clinical-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/slow-growing-lung-cancer-emerging-entity-screening-clinical-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/slow-growing-lung-cancer-emerging-entity-screening-clinical-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/histology-potential-clinical-predictor-outcome-advanced-non-small-cell-lung-cancer-treated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/histology-potential-clinical-predictor-outcome-advanced-non-small-cell-lung-cancer-treated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/histology-potential-clinical-predictor-outcome-advanced-non-small-cell-lung-cancer-treated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-schedule-dependency-study-aurora-kinase-inhibitor-msc1992371a-combination-gemcitabine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-schedule-dependency-study-aurora-kinase-inhibitor-msc1992371a-combination-gemcitabine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-schedule-dependency-study-aurora-kinase-inhibitor-msc1992371a-combination-gemcitabine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/preoperative-chemosensitivity-testing-predictor-treatment-benefit-adjuvant-stage-iii-colon-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/preoperative-chemosensitivity-testing-predictor-treatment-benefit-adjuvant-stage-iii-colon-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/preoperative-chemosensitivity-testing-predictor-treatment-benefit-adjuvant-stage-iii-colon-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tyrosinase-related-protein-1-mrna-expression-lymph-node-metastases-predicts-overall-survival-high 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tyrosinase-related-protein-1-mrna-expression-lymph-node-metastases-predicts-overall-survival-high 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tyrosinase-related-protein-1-mrna-expression-lymph-node-metastases-predicts-overall-survival-high 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/targeted-therapies-solid-cancers-new-options-new-challenges 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/targeted-therapies-solid-cancers-new-options-new-challenges 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/targeted-therapies-solid-cancers-new-options-new-challenges 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/crosstalk-between-her2-signaling-and-angiogenesis-breast-cancer-molecular-basis-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/crosstalk-between-her2-signaling-and-angiogenesis-breast-cancer-molecular-basis-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/crosstalk-between-her2-signaling-and-angiogenesis-breast-cancer-molecular-basis-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/academic-versus-industry-driven-research-upper-gastrointestinal-cancer-sinners-and-saints 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/academic-versus-industry-driven-research-upper-gastrointestinal-cancer-sinners-and-saints 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/academic-versus-industry-driven-research-upper-gastrointestinal-cancer-sinners-and-saints 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/systems-biology-cancer-entropy-disorder-and-selection-driven-evolution-independence-invasion-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/systems-biology-cancer-entropy-disorder-and-selection-driven-evolution-independence-invasion-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/systems-biology-cancer-entropy-disorder-and-selection-driven-evolution-independence-invasion-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/therapies-biologiques-ciblees-et-cancer-thyroidien-recidivant-enfin-un-standard-therapeutique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/therapies-biologiques-ciblees-et-cancer-thyroidien-recidivant-enfin-un-standard-therapeutique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/therapies-biologiques-ciblees-et-cancer-thyroidien-recidivant-enfin-un-standard-therapeutique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/vyznam-biomarkeru-v-klinicke-onkologii 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/vyznam-biomarkeru-v-klinicke-onkologii 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/vyznam-biomarkeru-v-klinicke-onkologii 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/adenopathies-cervicales-dans-le-suivi-d-une-lobectomie-inferieure-droite-cas-clinique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adenopathies-cervicales-dans-le-suivi-d-une-lobectomie-inferieure-droite-cas-clinique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adenopathies-cervicales-dans-le-suivi-d-une-lobectomie-inferieure-droite-cas-clinique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/chemoprevention-and-organ-preservation-programs-post-operative-management-major-achievements-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/chemoprevention-and-organ-preservation-programs-post-operative-management-major-achievements-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/chemoprevention-and-organ-preservation-programs-post-operative-management-major-achievements-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/neoadjuvant-chemotherapy-her2-inhibitors-breast-cancer-authors-reply 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/neoadjuvant-chemotherapy-her2-inhibitors-breast-cancer-authors-reply 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/neoadjuvant-chemotherapy-her2-inhibitors-breast-cancer-authors-reply 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cancer-du-sein-et-radiotherapie-peroperatoire-par-electrons-ioert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cancer-du-sein-et-radiotherapie-peroperatoire-par-electrons-ioert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cancer-du-sein-et-radiotherapie-peroperatoire-par-electrons-ioert 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/exploitation-de-la-spectrometrie-de-masse-en-microbiologie-une-revolution 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/exploitation-de-la-spectrometrie-de-masse-en-microbiologie-une-revolution 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/exploitation-de-la-spectrometrie-de-masse-en-microbiologie-une-revolution 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/causes-death-and-incidence-life-support-techniques-limitations-oncological-patients-dying-icu 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/causes-death-and-incidence-life-support-techniques-limitations-oncological-patients-dying-icu 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/causes-death-and-incidence-life-support-techniques-limitations-oncological-patients-dying-icu 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/atteintes-orbitaires-secondaires-des-cancers-systemiques-et-regionaux-louryan-s-lemort-m-ed 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/atteintes-orbitaires-secondaires-des-cancers-systemiques-et-regionaux-louryan-s-lemort-m-ed 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/atteintes-orbitaires-secondaires-des-cancers-systemiques-et-regionaux-louryan-s-lemort-m-ed 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/targeted-therapies-non-small-cell-lung-cancer-which-implication-routine-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/targeted-therapies-non-small-cell-lung-cancer-which-implication-routine-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/targeted-therapies-non-small-cell-lung-cancer-which-implication-routine-practice 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/atypical-presentation-and-localization-granulosa-cell-tumor-case-report-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/atypical-presentation-and-localization-granulosa-cell-tumor-case-report-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/atypical-presentation-and-localization-granulosa-cell-tumor-case-report-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/la-douleur-est-elle-une-norme-universelle 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/la-douleur-est-elle-une-norme-universelle 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/la-douleur-est-elle-une-norme-universelle 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/expression-profiling-who-classification-tumours-breast-chapter-1-invasive-breast-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/expression-profiling-who-classification-tumours-breast-chapter-1-invasive-breast-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/expression-profiling-who-classification-tumours-breast-chapter-1-invasive-breast-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/safety-and-efficacy-radioimmunotherapy-90yttrium-rituximab-patients-relapsed-cd20-b-cell-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/safety-and-efficacy-radioimmunotherapy-90yttrium-rituximab-patients-relapsed-cd20-b-cell-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/safety-and-efficacy-radioimmunotherapy-90yttrium-rituximab-patients-relapsed-cd20-b-cell-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/preface-de-cremoux-p-ed-signatures-moleculaires-des-cancers-l-innovation-therapeutique-en 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/preface-de-cremoux-p-ed-signatures-moleculaires-des-cancers-l-innovation-therapeutique-en 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/preface-de-cremoux-p-ed-signatures-moleculaires-des-cancers-l-innovation-therapeutique-en 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/quality-life-patients-head-and-neck-cancer-receiving-targeted-or-multimodal-therapy-update-eortc 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/quality-life-patients-head-and-neck-cancer-receiving-targeted-or-multimodal-therapy-update-eortc 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/quality-life-patients-head-and-neck-cancer-receiving-targeted-or-multimodal-therapy-update-eortc 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/radiotherapie-intra-operatoire-et-cancer-du-sein 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/radiotherapie-intra-operatoire-et-cancer-du-sein 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/radiotherapie-intra-operatoire-et-cancer-du-sein 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/le-souhait-d-aide-psychologique-des-patients-ages-atteints-d-un-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/le-souhait-d-aide-psychologique-des-patients-ages-atteints-d-un-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/le-souhait-d-aide-psychologique-des-patients-ages-atteints-d-un-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/role-and-interpretation-fdg-petct-hiv-patients-fever-unknown-origin-prospective-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/role-and-interpretation-fdg-petct-hiv-patients-fever-unknown-origin-prospective-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/role-and-interpretation-fdg-petct-hiv-patients-fever-unknown-origin-prospective-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/assessment-intrinsic-pluripotency-mesoderm-derived-stem-cells-different-niches 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/assessment-intrinsic-pluripotency-mesoderm-derived-stem-cells-different-niches 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/assessment-intrinsic-pluripotency-mesoderm-derived-stem-cells-different-niches 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-trial-design-head-and-neck-cancer-past-experiences-future-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-trial-design-head-and-neck-cancer-past-experiences-future-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-trial-design-head-and-neck-cancer-past-experiences-future-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/communication-skills-training-residents-which-variables-predict-learning-skills 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/communication-skills-training-residents-which-variables-predict-learning-skills 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/communication-skills-training-residents-which-variables-predict-learning-skills 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/anaplastic-lymphoma-kinase-alk-inhibitors-second-line-therapy-non-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/anaplastic-lymphoma-kinase-alk-inhibitors-second-line-therapy-non-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/anaplastic-lymphoma-kinase-alk-inhibitors-second-line-therapy-non-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/systemic-treatment-brain-metastases-her2-positive-breast-cancer-current-status-and-future 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/systemic-treatment-brain-metastases-her2-positive-breast-cancer-current-status-and-future 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/systemic-treatment-brain-metastases-her2-positive-breast-cancer-current-status-and-future 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/national-cohort-hiv-infected-patients-belgium-design-and-main-characteristics 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/national-cohort-hiv-infected-patients-belgium-design-and-main-characteristics 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/national-cohort-hiv-infected-patients-belgium-design-and-main-characteristics 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/subjective-cognitive-complaints-one-year-after-ceasing-adjuvant-endocrine-treatment-early-stage 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/subjective-cognitive-complaints-one-year-after-ceasing-adjuvant-endocrine-treatment-early-stage 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/subjective-cognitive-complaints-one-year-after-ceasing-adjuvant-endocrine-treatment-early-stage 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/radical-cystectomy-pro-laparoscopic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/radical-cystectomy-pro-laparoscopic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/radical-cystectomy-pro-laparoscopic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/carpal-tunnel-syndrome-and-musculoskeletal-symptoms-postmenopausal-women-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/carpal-tunnel-syndrome-and-musculoskeletal-symptoms-postmenopausal-women-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/carpal-tunnel-syndrome-and-musculoskeletal-symptoms-postmenopausal-women-early-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/papillary-thyroid-microcarcinoma-struma-ovarii 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/papillary-thyroid-microcarcinoma-struma-ovarii 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/papillary-thyroid-microcarcinoma-struma-ovarii 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/are-there-several-kinds-palliative-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/are-there-several-kinds-palliative-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/are-there-several-kinds-palliative-care 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evolution-and-simplified-terminology-natural-orifice-transluminal-endoscopic-surgery-notes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evolution-and-simplified-terminology-natural-orifice-transluminal-endoscopic-surgery-notes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evolution-and-simplified-terminology-natural-orifice-transluminal-endoscopic-surgery-notes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/expression-prognostic-and-predictive-impact-vegf-and-bfgf-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/expression-prognostic-and-predictive-impact-vegf-and-bfgf-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/expression-prognostic-and-predictive-impact-vegf-and-bfgf-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/long-term-results-randomized-phase-iii-trial-eortc-18991-adjuvant-therapy-pegylated-interferon-alfa 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/long-term-results-randomized-phase-iii-trial-eortc-18991-adjuvant-therapy-pegylated-interferon-alfa 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/long-term-results-randomized-phase-iii-trial-eortc-18991-adjuvant-therapy-pegylated-interferon-alfa 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/ulceration-and-stage-are-predictive-interferon-efficacy-melanoma-results-phase-iii-adjuvant-trials 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/ulceration-and-stage-are-predictive-interferon-efficacy-melanoma-results-phase-iii-adjuvant-trials 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/ulceration-and-stage-are-predictive-interferon-efficacy-melanoma-results-phase-iii-adjuvant-trials 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/long-term-surveillance-papillary-thyroid-cancer-patients-who-do-not-undergo-postoperative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/long-term-surveillance-papillary-thyroid-cancer-patients-who-do-not-undergo-postoperative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/long-term-surveillance-papillary-thyroid-cancer-patients-who-do-not-undergo-postoperative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/choosing-best-trastuzumab-based-adjuvant-chemotherapy-regimen-should-we-abandon-anthracyclines 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/choosing-best-trastuzumab-based-adjuvant-chemotherapy-regimen-should-we-abandon-anthracyclines 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/choosing-best-trastuzumab-based-adjuvant-chemotherapy-regimen-should-we-abandon-anthracyclines 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/postoperative-radiotherapy-after-radical-prostatectomy-high-risk-prostate-cancer-long-term-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/postoperative-radiotherapy-after-radical-prostatectomy-high-risk-prostate-cancer-long-term-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/postoperative-radiotherapy-after-radical-prostatectomy-high-risk-prostate-cancer-long-term-results 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/bone-metastasis-breast-cancer-story-rank-ligand 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bone-metastasis-breast-cancer-story-rank-ligand 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bone-metastasis-breast-cancer-story-rank-ligand 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prognosis-pregnancy-associated-breast-cancer-meta-analysis-30-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prognosis-pregnancy-associated-breast-cancer-meta-analysis-30-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prognosis-pregnancy-associated-breast-cancer-meta-analysis-30-studies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-suppressor-candidate-1-bcsc-1-melanoma-tumor-suppressor-down-regulates-mitf 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-suppressor-candidate-1-bcsc-1-melanoma-tumor-suppressor-down-regulates-mitf 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-suppressor-candidate-1-bcsc-1-melanoma-tumor-suppressor-down-regulates-mitf 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/deep-sequencing-reveals-abundant-noncanonical-retroviral-micrornas-b-cell-leukemialymphoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/deep-sequencing-reveals-abundant-noncanonical-retroviral-micrornas-b-cell-leukemialymphoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/deep-sequencing-reveals-abundant-noncanonical-retroviral-micrornas-b-cell-leukemialymphoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pomalidomide-plus-low-dose-dexamethasone-active-and-well-tolerated-bortezomib-and-lenalidomide 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/pomalidomide-plus-low-dose-dexamethasone-active-and-well-tolerated-bortezomib-and-lenalidomide 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/pomalidomide-plus-low-dose-dexamethasone-active-and-well-tolerated-bortezomib-and-lenalidomide 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/pik3ca-genotype-and-pik3ca-mutation-related-gene-signature-and-response-everolimus-and-letrozole 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pik3ca-genotype-and-pik3ca-mutation-related-gene-signature-and-response-everolimus-and-letrozole 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pik3ca-genotype-and-pik3ca-mutation-related-gene-signature-and-response-everolimus-and-letrozole 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/13th-meeting-cancer-related-emergencies-and-cancer-related-severe-complications 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/13th-meeting-cancer-related-emergencies-and-cancer-related-severe-complications 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/13th-meeting-cancer-related-emergencies-and-cancer-related-severe-complications 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/additional-prognostic-value-70-gene-signature-mammaprintr-among-breast-cancer-patients-4-9-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/additional-prognostic-value-70-gene-signature-mammaprintr-among-breast-cancer-patients-4-9-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/additional-prognostic-value-70-gene-signature-mammaprintr-among-breast-cancer-patients-4-9-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/effect-everolimus-bone-marker-levels-and-progressive-disease-bone-bolero-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/effect-everolimus-bone-marker-levels-and-progressive-disease-bone-bolero-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/effect-everolimus-bone-marker-levels-and-progressive-disease-bone-bolero-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/single-access-laparoscopic-primary-and-incisional-prosthetic-hernia-repair-first-50-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/single-access-laparoscopic-primary-and-incisional-prosthetic-hernia-repair-first-50-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/single-access-laparoscopic-primary-and-incisional-prosthetic-hernia-repair-first-50-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/circulating-mir-150-and-mir-342-plasma-are-novel-potential-biomarkers-acute-myeloid-leukemia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/circulating-mir-150-and-mir-342-plasma-are-novel-potential-biomarkers-acute-myeloid-leukemia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/circulating-mir-150-and-mir-342-plasma-are-novel-potential-biomarkers-acute-myeloid-leukemia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/intrathecal-trastuzumab-treatment-neoplastic-meningitis-due-breast-cancer-case-report-and-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/intrathecal-trastuzumab-treatment-neoplastic-meningitis-due-breast-cancer-case-report-and-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/intrathecal-trastuzumab-treatment-neoplastic-meningitis-due-breast-cancer-case-report-and-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/overall-survival-benefit-sequential-doxorubicin-docetaxel-compared-concurrent-doxorubicin-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/overall-survival-benefit-sequential-doxorubicin-docetaxel-compared-concurrent-doxorubicin-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/overall-survival-benefit-sequential-doxorubicin-docetaxel-compared-concurrent-doxorubicin-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/high-risk-human-papillomavirus-infection-hiv-positive-african-women-living-europe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/high-risk-human-papillomavirus-infection-hiv-positive-african-women-living-europe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/high-risk-human-papillomavirus-infection-hiv-positive-african-women-living-europe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/analysis-regional-timelines-set-global-phase-iii-clinical-trial-breast-cancer-adjuvant-lapatinib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/analysis-regional-timelines-set-global-phase-iii-clinical-trial-breast-cancer-adjuvant-lapatinib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/analysis-regional-timelines-set-global-phase-iii-clinical-trial-breast-cancer-adjuvant-lapatinib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prognostic-and-predictive-value-tumor-infiltrating-lymphocytes-phase-iii-randomized-adjuvant-breast 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-and-predictive-value-tumor-infiltrating-lymphocytes-phase-iii-randomized-adjuvant-breast 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-and-predictive-value-tumor-infiltrating-lymphocytes-phase-iii-randomized-adjuvant-breast 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/cns-relapses-patients-her2-positive-early-breast-cancer-who-have-and-have-not-received-adjuvant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cns-relapses-patients-her2-positive-early-breast-cancer-who-have-and-have-not-received-adjuvant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cns-relapses-patients-her2-positive-early-breast-cancer-who-have-and-have-not-received-adjuvant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/relevance-systematic-geriatric-screening-and-assessment-older-patients-cancer-results-prospective 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/relevance-systematic-geriatric-screening-and-assessment-older-patients-cancer-results-prospective 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/relevance-systematic-geriatric-screening-and-assessment-older-patients-cancer-results-prospective 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/oncological-intensive-care-2011-year-s-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/oncological-intensive-care-2011-year-s-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/oncological-intensive-care-2011-year-s-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lung-cancer-patient-emergency-department-three-year-retrospective-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/lung-cancer-patient-emergency-department-three-year-retrospective-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/lung-cancer-patient-emergency-department-three-year-retrospective-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-study-oral-cp-4126-gemcitabine-derivative-patients-advanced-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-study-oral-cp-4126-gemcitabine-derivative-patients-advanced-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-study-oral-cp-4126-gemcitabine-derivative-patients-advanced-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/oral-antibiotics-fever-low-risk-neutropenic-patients-cancer-double-blind-randomized-multicenter 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/oral-antibiotics-fever-low-risk-neutropenic-patients-cancer-double-blind-randomized-multicenter 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/oral-antibiotics-fever-low-risk-neutropenic-patients-cancer-double-blind-randomized-multicenter 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/heterogeneity-and-evolution-thymidine-kinase-and-dna-polymerase-mutants-herpes-simplex-virus-type-1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/heterogeneity-and-evolution-thymidine-kinase-and-dna-polymerase-mutants-herpes-simplex-virus-type-1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/heterogeneity-and-evolution-thymidine-kinase-and-dna-polymerase-mutants-herpes-simplex-virus-type-1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/richard-doll-surprising-story-conflicts-interest 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/richard-doll-surprising-story-conflicts-interest 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/richard-doll-surprising-story-conflicts-interest 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/13eme-journee-annuelle-d-oncologie-thoracique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/13eme-journee-annuelle-d-oncologie-thoracique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/13eme-journee-annuelle-d-oncologie-thoracique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-salivary-gland-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-salivary-gland-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-salivary-gland-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/observation-cytopathogenic-effect-cell-lines-used-routine-viral-cultures-led-diagnosis 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/observation-cytopathogenic-effect-cell-lines-used-routine-viral-cultures-led-diagnosis 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/observation-cytopathogenic-effect-cell-lines-used-routine-viral-cultures-led-diagnosis 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/comparison-prognostic-value-genomic-grade-index-ki67-expression-and-mitotic-activity-index-early 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/comparison-prognostic-value-genomic-grade-index-ki67-expression-and-mitotic-activity-index-early 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/comparison-prognostic-value-genomic-grade-index-ki67-expression-and-mitotic-activity-index-early 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/molecular-subclasses-breast-cancer-how-do-we-define-them-impakt-2012-working-group-statement-0 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/molecular-subclasses-breast-cancer-how-do-we-define-them-impakt-2012-working-group-statement-0 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/molecular-subclasses-breast-cancer-how-do-we-define-them-impakt-2012-working-group-statement-0 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/molecular-pathways-involvement-immune-pathways-therapeutic-response-and-outcome-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/molecular-pathways-involvement-immune-pathways-therapeutic-response-and-outcome-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/molecular-pathways-involvement-immune-pathways-therapeutic-response-and-outcome-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-application-circulating-tumor-cells-breast-cancer-overview-current-interventional-trials 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-application-circulating-tumor-cells-breast-cancer-overview-current-interventional-trials 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-application-circulating-tumor-cells-breast-cancer-overview-current-interventional-trials 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/non-malignant-causes-hypercalcemia-cancer-patients-frequent-and-neglected-occurrence 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/non-malignant-causes-hypercalcemia-cancer-patients-frequent-and-neglected-occurrence 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/non-malignant-causes-hypercalcemia-cancer-patients-frequent-and-neglected-occurrence 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/noninvasive-mechanical-ventilation-patients-having-declined-tracheal-intubation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/noninvasive-mechanical-ventilation-patients-having-declined-tracheal-intubation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/noninvasive-mechanical-ventilation-patients-having-declined-tracheal-intubation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/open-label-extension-study-investigate-long-term-safety-and-tolerability-thccbd-oromucosal-spray 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/open-label-extension-study-investigate-long-term-safety-and-tolerability-thccbd-oromucosal-spray 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/open-label-extension-study-investigate-long-term-safety-and-tolerability-thccbd-oromucosal-spray 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-study-pulsatile-3-day-administration-afatinib-bibw-2992-combination-docetaxel-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-study-pulsatile-3-day-administration-afatinib-bibw-2992-combination-docetaxel-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-study-pulsatile-3-day-administration-afatinib-bibw-2992-combination-docetaxel-advanced 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/comparison-pet-metabolic-indices-early-assessment-tumour-response-metastatic-colorectal-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/comparison-pet-metabolic-indices-early-assessment-tumour-response-metastatic-colorectal-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/comparison-pet-metabolic-indices-early-assessment-tumour-response-metastatic-colorectal-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/cardiovascular-toxicity-induced-chemotherapy-targeted-agents-and-radiotherapy-esmo-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cardiovascular-toxicity-induced-chemotherapy-targeted-agents-and-radiotherapy-esmo-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cardiovascular-toxicity-induced-chemotherapy-targeted-agents-and-radiotherapy-esmo-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/hdac-isoenzyme-expression-deregulated-chronic-lymphocytic-leukemia-b-cells-and-has-complex 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/hdac-isoenzyme-expression-deregulated-chronic-lymphocytic-leukemia-b-cells-and-has-complex 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/hdac-isoenzyme-expression-deregulated-chronic-lymphocytic-leukemia-b-cells-and-has-complex 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/gonadotropin-releasing-hormone-agonist-prevention-chemotherapy-induced-ovarian-failure-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/gonadotropin-releasing-hormone-agonist-prevention-chemotherapy-induced-ovarian-failure-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/gonadotropin-releasing-hormone-agonist-prevention-chemotherapy-induced-ovarian-failure-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/stem-cell-transplantation-can-provide-durable-disease-control-blastic-plasmacytoid-dendritic-cell 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/stem-cell-transplantation-can-provide-durable-disease-control-blastic-plasmacytoid-dendritic-cell 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/stem-cell-transplantation-can-provide-durable-disease-control-blastic-plasmacytoid-dendritic-cell 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/erratum-immune-related-antigens-surface-molecules-and-regulatory-factors-human-derived-mesenchymal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/erratum-immune-related-antigens-surface-molecules-and-regulatory-factors-human-derived-mesenchymal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/erratum-immune-related-antigens-surface-molecules-and-regulatory-factors-human-derived-mesenchymal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/efficacy-and-toxicity-two-schedules-bortezomib-patients-recurrent-or-refractory-follicular-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/efficacy-and-toxicity-two-schedules-bortezomib-patients-recurrent-or-refractory-follicular-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/efficacy-and-toxicity-two-schedules-bortezomib-patients-recurrent-or-refractory-follicular-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/optimizing-taxane-use-mbc-emerging-era-targeted-chemotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/optimizing-taxane-use-mbc-emerging-era-targeted-chemotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/optimizing-taxane-use-mbc-emerging-era-targeted-chemotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/mrna-expression-papillary-and-anaplastic-thyroid-carcinoma-molecular-anatomy-killing-switch 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/mrna-expression-papillary-and-anaplastic-thyroid-carcinoma-molecular-anatomy-killing-switch 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/mrna-expression-papillary-and-anaplastic-thyroid-carcinoma-molecular-anatomy-killing-switch 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/follow-strategies-head-and-neck-cancer-other-upper-aerodigestive-tract-squamous-cell-carcinoma-epub 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/follow-strategies-head-and-neck-cancer-other-upper-aerodigestive-tract-squamous-cell-carcinoma-epub 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/follow-strategies-head-and-neck-cancer-other-upper-aerodigestive-tract-squamous-cell-carcinoma-epub 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/5-aza-2-deoxycytidine-has-minor-effects-differentiation-human-thyroid-cancer-cell-lines-modulates 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/5-aza-2-deoxycytidine-has-minor-effects-differentiation-human-thyroid-cancer-cell-lines-modulates 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/5-aza-2-deoxycytidine-has-minor-effects-differentiation-human-thyroid-cancer-cell-lines-modulates 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/adjuvant-lapatinib-women-early-stage-her2-positive-breast-cancer-randomised-controlled-phase-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adjuvant-lapatinib-women-early-stage-her2-positive-breast-cancer-randomised-controlled-phase-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adjuvant-lapatinib-women-early-stage-her2-positive-breast-cancer-randomised-controlled-phase-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-study-lonafarnib-sch66336-combination-trastuzumab-plus-paclitaxel-her2neu-overexpressing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-study-lonafarnib-sch66336-combination-trastuzumab-plus-paclitaxel-her2neu-overexpressing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-study-lonafarnib-sch66336-combination-trastuzumab-plus-paclitaxel-her2neu-overexpressing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prognostic-impact-pregnancy-after-breast-cancer-according-estrogen-receptor-status-multicenter 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-impact-pregnancy-after-breast-cancer-according-estrogen-receptor-status-multicenter 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-impact-pregnancy-after-breast-cancer-according-estrogen-receptor-status-multicenter 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/risk-adjusted-benchmarking-abdominoperineal-excision-rectal-adenocarcinoma-context-belgian-procare 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/risk-adjusted-benchmarking-abdominoperineal-excision-rectal-adenocarcinoma-context-belgian-procare 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/risk-adjusted-benchmarking-abdominoperineal-excision-rectal-adenocarcinoma-context-belgian-procare 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-development-insulin-growth-factor-receptor-1-igf-1r-inhibitors-crossroad 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-development-insulin-growth-factor-receptor-1-igf-1r-inhibitors-crossroad 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-development-insulin-growth-factor-receptor-1-igf-1r-inhibitors-crossroad 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/urine-iodide-determination-ion-pair-reversed-phase-high-performance-liquid-chromatography-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/urine-iodide-determination-ion-pair-reversed-phase-high-performance-liquid-chromatography-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/urine-iodide-determination-ion-pair-reversed-phase-high-performance-liquid-chromatography-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/triple-negative-breast-cancer-focus-biology-novel-therapeutics-editorial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/triple-negative-breast-cancer-focus-biology-novel-therapeutics-editorial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/triple-negative-breast-cancer-focus-biology-novel-therapeutics-editorial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/antimicrobial-susceptibility-streptococcus-pneumoniae-isolates-vaccinated-and-non-vaccinated 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/antimicrobial-susceptibility-streptococcus-pneumoniae-isolates-vaccinated-and-non-vaccinated 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/antimicrobial-susceptibility-streptococcus-pneumoniae-isolates-vaccinated-and-non-vaccinated 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/incidence-and-virulence-determinants-verocytotoxin-producing-escherichia-coli-infections-brussels 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/incidence-and-virulence-determinants-verocytotoxin-producing-escherichia-coli-infections-brussels 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/incidence-and-virulence-determinants-verocytotoxin-producing-escherichia-coli-infections-brussels 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/performance-individual-helicobacter-pylori-antigens-immunoblot-based-detection-h-pylori-infection 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/performance-individual-helicobacter-pylori-antigens-immunoblot-based-detection-h-pylori-infection 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/performance-individual-helicobacter-pylori-antigens-immunoblot-based-detection-h-pylori-infection 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/management-cryptosporidium-hominis-outbreak-day-care-center 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/management-cryptosporidium-hominis-outbreak-day-care-center 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/management-cryptosporidium-hominis-outbreak-day-care-center 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/prospective-evaluation-coris-influ-ab-respi-strip-and-binaxnow-influenza-ab-assay-against-viral 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/prospective-evaluation-coris-influ-ab-respi-strip-and-binaxnow-influenza-ab-assay-against-viral 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/prospective-evaluation-coris-influ-ab-respi-strip-and-binaxnow-influenza-ab-assay-against-viral 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/comparison-microflex-lt-and-vitek-ms-systems-routine-identification-bacteria-matrix-assisted-laser 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/comparison-microflex-lt-and-vitek-ms-systems-routine-identification-bacteria-matrix-assisted-laser 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/comparison-microflex-lt-and-vitek-ms-systems-routine-identification-bacteria-matrix-assisted-laser 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/evaluation-commercial-screening-tests-and-blot-assays-diagnosis-lyme-borreliosis 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-commercial-screening-tests-and-blot-assays-diagnosis-lyme-borreliosis 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-commercial-screening-tests-and-blot-assays-diagnosis-lyme-borreliosis 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/comparison-house-method-and-commercial-sepsitypertm-kit-bacterial-identification-directly-positive 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/comparison-house-method-and-commercial-sepsitypertm-kit-bacterial-identification-directly-positive 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/comparison-house-method-and-commercial-sepsitypertm-kit-bacterial-identification-directly-positive 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/human-papillomavirus-dna-strongly-correlates-poorer-prognosis-oral-cavity-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/human-papillomavirus-dna-strongly-correlates-poorer-prognosis-oral-cavity-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/human-papillomavirus-dna-strongly-correlates-poorer-prognosis-oral-cavity-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/percutaneous-endoscopic-jejunostomy-patients-gastroparesis-following-lung-transplantation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/percutaneous-endoscopic-jejunostomy-patients-gastroparesis-following-lung-transplantation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/percutaneous-endoscopic-jejunostomy-patients-gastroparesis-following-lung-transplantation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/esophageal-self-expanding-metallic-stent-sems-migration-it-s-topsy-turvy-world 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/esophageal-self-expanding-metallic-stent-sems-migration-it-s-topsy-turvy-world 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/esophageal-self-expanding-metallic-stent-sems-migration-it-s-topsy-turvy-world 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/has-removal-excess-cysteine-led-evolution-pheomelanin-pheomelanogenesis-excretory-mechanism 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/has-removal-excess-cysteine-led-evolution-pheomelanin-pheomelanogenesis-excretory-mechanism 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/has-removal-excess-cysteine-led-evolution-pheomelanin-pheomelanogenesis-excretory-mechanism 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/mdm4-key-therapeutic-target-cutaneous-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/mdm4-key-therapeutic-target-cutaneous-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/mdm4-key-therapeutic-target-cutaneous-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/functional-status-and-relationships-melanocortin-1-receptor-signaling-camp-and-extracellular-signal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/functional-status-and-relationships-melanocortin-1-receptor-signaling-camp-and-extracellular-signal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/functional-status-and-relationships-melanocortin-1-receptor-signaling-camp-and-extracellular-signal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/survey-concerning-exposure-staff-uv-radiation-four-brussels-hospitals 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/survey-concerning-exposure-staff-uv-radiation-four-brussels-hospitals 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/survey-concerning-exposure-staff-uv-radiation-four-brussels-hospitals 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/complications-mesh-repair-hiatal-surgery-about-3-cases-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/complications-mesh-repair-hiatal-surgery-about-3-cases-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/complications-mesh-repair-hiatal-surgery-about-3-cases-and-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/minimal-residual-disease-and-circulating-tumor-cells-breast-cancer-open-questions-research 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/minimal-residual-disease-and-circulating-tumor-cells-breast-cancer-open-questions-research 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/minimal-residual-disease-and-circulating-tumor-cells-breast-cancer-open-questions-research 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/understanding-biology-triple-negative-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/understanding-biology-triple-negative-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/understanding-biology-triple-negative-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/distinct-tumor-protein-p53-mutants-breast-cancer-subgroups 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/distinct-tumor-protein-p53-mutants-breast-cancer-subgroups 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/distinct-tumor-protein-p53-mutants-breast-cancer-subgroups 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pertuzumab-new-hope-patients-her2-positive-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/pertuzumab-new-hope-patients-her2-positive-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/pertuzumab-new-hope-patients-her2-positive-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/decision-making-oncology-selected-literature-review-and-some-recommendations-future 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/decision-making-oncology-selected-literature-review-and-some-recommendations-future 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/decision-making-oncology-selected-literature-review-and-some-recommendations-future 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/desire-formal-psychological-support-among-caregivers-patients-cancer-prevalence-and-implications 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/desire-formal-psychological-support-among-caregivers-patients-cancer-prevalence-and-implications 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/desire-formal-psychological-support-among-caregivers-patients-cancer-prevalence-and-implications 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/common-language-neoadjuvant-breast-cancer-clinical-trials-proposals-standard-definitions-and 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/common-language-neoadjuvant-breast-cancer-clinical-trials-proposals-standard-definitions-and 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/common-language-neoadjuvant-breast-cancer-clinical-trials-proposals-standard-definitions-and 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/liquid-biopsy-test-new-treatment-strategies-breast-cancer-are-we-there-yet 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/liquid-biopsy-test-new-treatment-strategies-breast-cancer-are-we-there-yet 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/liquid-biopsy-test-new-treatment-strategies-breast-cancer-are-we-there-yet 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-ii-randomized-study-combined-infusional-leucovorin-sodium-and-5-fu-versus-leucovorin-calcium 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-ii-randomized-study-combined-infusional-leucovorin-sodium-and-5-fu-versus-leucovorin-calcium 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-ii-randomized-study-combined-infusional-leucovorin-sodium-and-5-fu-versus-leucovorin-calcium 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/update-evolution-breast-cancer-incidence-relation-hormone-replacement-therapy-use-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/update-evolution-breast-cancer-incidence-relation-hormone-replacement-therapy-use-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/update-evolution-breast-cancer-incidence-relation-hormone-replacement-therapy-use-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/microrna-profile-circulating-cd4-positive-regulatory-t-cells-human-adults-and-impact-differentially 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/microrna-profile-circulating-cd4-positive-regulatory-t-cells-human-adults-and-impact-differentially 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/microrna-profile-circulating-cd4-positive-regulatory-t-cells-human-adults-and-impact-differentially 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/prognostic-and-predictive-value-tp53-mutations-node-positive-breast-cancer-patients-treated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-and-predictive-value-tp53-mutations-node-positive-breast-cancer-patients-treated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-and-predictive-value-tp53-mutations-node-positive-breast-cancer-patients-treated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/mesoderm-derived-stem-cells-link-between-transcriptome-and-their-differentiation-potential 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/mesoderm-derived-stem-cells-link-between-transcriptome-and-their-differentiation-potential 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/mesoderm-derived-stem-cells-link-between-transcriptome-and-their-differentiation-potential 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/confusion-around-neuroendocrine-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/confusion-around-neuroendocrine-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/confusion-around-neuroendocrine-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/intrapatient-cetuximab-dose-escalation-metastatic-colorectal-cancer-according-grade-early-skin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/intrapatient-cetuximab-dose-escalation-metastatic-colorectal-cancer-according-grade-early-skin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/intrapatient-cetuximab-dose-escalation-metastatic-colorectal-cancer-according-grade-early-skin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/elucidating-prognosis-and-biology-breast-cancer-arising-young-women-using-gene-expression-profiling 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/elucidating-prognosis-and-biology-breast-cancer-arising-young-women-using-gene-expression-profiling 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/elucidating-prognosis-and-biology-breast-cancer-arising-young-women-using-gene-expression-profiling 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-periprosthetic-fractures-patients-treated-megaprosthesis-malignant-bone-tumours-around 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-periprosthetic-fractures-patients-treated-megaprosthesis-malignant-bone-tumours-around 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-periprosthetic-fractures-patients-treated-megaprosthesis-malignant-bone-tumours-around 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/new-pet-imaging-agents-management-solid-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/new-pet-imaging-agents-management-solid-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/new-pet-imaging-agents-management-solid-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lesion-based-detection-early-chemosensitivity-using-serial-static-fdg-petct-metastatic-colorectal 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/lesion-based-detection-early-chemosensitivity-using-serial-static-fdg-petct-metastatic-colorectal 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/lesion-based-detection-early-chemosensitivity-using-serial-static-fdg-petct-metastatic-colorectal 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/characterization-and-clinical-evaluation-cd10-stroma-cells-breast-cancer-microenvironment 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/characterization-and-clinical-evaluation-cd10-stroma-cells-breast-cancer-microenvironment 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/characterization-and-clinical-evaluation-cd10-stroma-cells-breast-cancer-microenvironment 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/three-gene-model-robustly-identify-breast-cancer-molecular-subtypes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/three-gene-model-robustly-identify-breast-cancer-molecular-subtypes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/three-gene-model-robustly-identify-breast-cancer-molecular-subtypes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/landscape-cancer-genes-and-mutational-processes-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/landscape-cancer-genes-and-mutational-processes-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/landscape-cancer-genes-and-mutational-processes-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/gene-modules-and-response-neoadjuvant-chemotherapy-breast-cancer-subtypes-pooled-analysis 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/gene-modules-and-response-neoadjuvant-chemotherapy-breast-cancer-subtypes-pooled-analysis 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/gene-modules-and-response-neoadjuvant-chemotherapy-breast-cancer-subtypes-pooled-analysis 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/molecular-biology-breast-cancer-should-molecular-classifiers-be-assessed-conventional-tools-or-gene 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/molecular-biology-breast-cancer-should-molecular-classifiers-be-assessed-conventional-tools-or-gene 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/molecular-biology-breast-cancer-should-molecular-classifiers-be-assessed-conventional-tools-or-gene 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/next-generation-sequencing-breast-cancer-first-take-home-messages 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/next-generation-sequencing-breast-cancer-first-take-home-messages 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/next-generation-sequencing-breast-cancer-first-take-home-messages 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/treatment-options-anthracycline-andor-taxane-pretreated-patients-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/treatment-options-anthracycline-andor-taxane-pretreated-patients-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/treatment-options-anthracycline-andor-taxane-pretreated-patients-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/bevacizumab-and-breast-cancer-meta-analysis-first-line-phase-iii-studies-and-critical-reappraisal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/bevacizumab-and-breast-cancer-meta-analysis-first-line-phase-iii-studies-and-critical-reappraisal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/bevacizumab-and-breast-cancer-meta-analysis-first-line-phase-iii-studies-and-critical-reappraisal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/lapatinib-trastuzumab-her2-positive-early-breast-cancer-neoaltto-randomised-open-label-multicentre 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lapatinib-trastuzumab-her2-positive-early-breast-cancer-neoaltto-randomised-open-label-multicentre 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lapatinib-trastuzumab-her2-positive-early-breast-cancer-neoaltto-randomised-open-label-multicentre 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pregnancy-occurring-during-or-following-adjuvant-trastuzumab-patients-enrolled-hera-trial-big-01-01 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pregnancy-occurring-during-or-following-adjuvant-trastuzumab-patients-enrolled-hera-trial-big-01-01 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pregnancy-occurring-during-or-following-adjuvant-trastuzumab-patients-enrolled-hera-trial-big-01-01 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/dissecting-heterogeneity-triple-negative-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/dissecting-heterogeneity-triple-negative-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/dissecting-heterogeneity-triple-negative-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/targeted-therapies-breast-cancer-are-heart-and-vessels-also-being-targeted 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/targeted-therapies-breast-cancer-are-heart-and-vessels-also-being-targeted 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/targeted-therapies-breast-cancer-are-heart-and-vessels-also-being-targeted 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/dual-human-epidermal-growth-factor-receptor-2-blockade-another-step-forward-treating-patients-human 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/dual-human-epidermal-growth-factor-receptor-2-blockade-another-step-forward-treating-patients-human 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/dual-human-epidermal-growth-factor-receptor-2-blockade-another-step-forward-treating-patients-human 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/genomic-grade-adds-prognostic-value-invasive-lobular-carcinoma-0 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/genomic-grade-adds-prognostic-value-invasive-lobular-carcinoma-0 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/genomic-grade-adds-prognostic-value-invasive-lobular-carcinoma-0 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/myc-diffuse-large-b-cell-lymphoma-not-salvaged-classical-r-ice-or-r-dhap-followed-beam-plus 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/myc-diffuse-large-b-cell-lymphoma-not-salvaged-classical-r-ice-or-r-dhap-followed-beam-plus 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/myc-diffuse-large-b-cell-lymphoma-not-salvaged-classical-r-ice-or-r-dhap-followed-beam-plus 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/inflammation-and-toll-receptor-ligation-differentially-affect-osteogenic-potential-human 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/inflammation-and-toll-receptor-ligation-differentially-affect-osteogenic-potential-human 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/inflammation-and-toll-receptor-ligation-differentially-affect-osteogenic-potential-human 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/characterization-and-functionality-cd200-cd200r-system-during-mesenchymal-stromal-cell-interactions 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/characterization-and-functionality-cd200-cd200r-system-during-mesenchymal-stromal-cell-interactions 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/characterization-and-functionality-cd200-cd200r-system-during-mesenchymal-stromal-cell-interactions 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/immune-related-antigens-surface-molecules-and-regulatory-factors-human-derived-mesenchymal-stromal 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immune-related-antigens-surface-molecules-and-regulatory-factors-human-derived-mesenchymal-stromal 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immune-related-antigens-surface-molecules-and-regulatory-factors-human-derived-mesenchymal-stromal 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/radioembolization-spleen-revisited-approach-treatment-malignant-lymphomatous-splenomegaly-epub 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/radioembolization-spleen-revisited-approach-treatment-malignant-lymphomatous-splenomegaly-epub 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/radioembolization-spleen-revisited-approach-treatment-malignant-lymphomatous-splenomegaly-epub 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/final-results-and-pharmacoeconomic-analysis-trial-comparing-two-neoadjuvant-chemotherapy-ct 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/final-results-and-pharmacoeconomic-analysis-trial-comparing-two-neoadjuvant-chemotherapy-ct 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/final-results-and-pharmacoeconomic-analysis-trial-comparing-two-neoadjuvant-chemotherapy-ct 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/euthanasia-ethical-debate-clinical-reality 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/euthanasia-ethical-debate-clinical-reality 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/euthanasia-ethical-debate-clinical-reality 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/technological-innovation-and-healthcare-professionals-workloads-ambiguous-relationship 2020-09-07T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-trial-investigate-safety-pharmacokinetics-and-efficacy-sorafenib-combined-docetaxel 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-trial-investigate-safety-pharmacokinetics-and-efficacy-sorafenib-combined-docetaxel 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-trial-investigate-safety-pharmacokinetics-and-efficacy-sorafenib-combined-docetaxel 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/second-primary-cancers-head-and-neck-cancer-patients-challenging-entity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/second-primary-cancers-head-and-neck-cancer-patients-challenging-entity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/second-primary-cancers-head-and-neck-cancer-patients-challenging-entity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-development-new-formulations-cytotoxics-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-development-new-formulations-cytotoxics-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-development-new-formulations-cytotoxics-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/personalized-management-patients-solid-cancers-moving-patient-characteristics-tumor-biology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/personalized-management-patients-solid-cancers-moving-patient-characteristics-tumor-biology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/personalized-management-patients-solid-cancers-moving-patient-characteristics-tumor-biology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/new-therapies-her2-positive-breast-cancer-major-step-towards-cure-disease 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/new-therapies-her2-positive-breast-cancer-major-step-towards-cure-disease 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/new-therapies-her2-positive-breast-cancer-major-step-towards-cure-disease 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-ii-trial-assess-efficacy-and-safety-afatinib-extensively-pretreated-patients-her2-negative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-ii-trial-assess-efficacy-and-safety-afatinib-extensively-pretreated-patients-her2-negative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-ii-trial-assess-efficacy-and-safety-afatinib-extensively-pretreated-patients-her2-negative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-and-pharmacokinetic-study-sunitinib-and-docetaxel-women-advanced-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-and-pharmacokinetic-study-sunitinib-and-docetaxel-women-advanced-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-and-pharmacokinetic-study-sunitinib-and-docetaxel-women-advanced-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/vandetanib-locally-advanced-or-metastatic-differentiated-thyroid-cancer-randomised-double-blind 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/vandetanib-locally-advanced-or-metastatic-differentiated-thyroid-cancer-randomised-double-blind 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/vandetanib-locally-advanced-or-metastatic-differentiated-thyroid-cancer-randomised-double-blind 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/safety-and-efficacy-neratinib-hki-272-plus-vinorelbine-treatment-patients-erbb2-positive-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/safety-and-efficacy-neratinib-hki-272-plus-vinorelbine-treatment-patients-erbb2-positive-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/safety-and-efficacy-neratinib-hki-272-plus-vinorelbine-treatment-patients-erbb2-positive-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/non-hiv-kaposi-s-sarcoma-review-and-therapeutic-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/non-hiv-kaposi-s-sarcoma-review-and-therapeutic-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/non-hiv-kaposi-s-sarcoma-review-and-therapeutic-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/m-ficolin-levels-are-associated-occurrence-severe-infections-patients-haematological-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/m-ficolin-levels-are-associated-occurrence-severe-infections-patients-haematological-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/m-ficolin-levels-are-associated-occurrence-severe-infections-patients-haematological-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/therapeutic-drug-monitoring-posaconazole-patients-acute-myeloid-leukemia-or-myelodysplasic-syndrome 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/therapeutic-drug-monitoring-posaconazole-patients-acute-myeloid-leukemia-or-myelodysplasic-syndrome 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/therapeutic-drug-monitoring-posaconazole-patients-acute-myeloid-leukemia-or-myelodysplasic-syndrome 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/mastocytosis-revisited-new-cytogenetic-data 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/mastocytosis-revisited-new-cytogenetic-data 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/mastocytosis-revisited-new-cytogenetic-data 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/role-epac-and-protein-kinase-thyrotropin-induced-gene-expression-primary-thyrocytes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/role-epac-and-protein-kinase-thyrotropin-induced-gene-expression-primary-thyrocytes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/role-epac-and-protein-kinase-thyrotropin-induced-gene-expression-primary-thyrocytes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/post-therapeutic-surveillance-strategies-head-and-neck-squamous-cell-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/post-therapeutic-surveillance-strategies-head-and-neck-squamous-cell-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/post-therapeutic-surveillance-strategies-head-and-neck-squamous-cell-carcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/eortc-24051-unexpected-side-effects-phase-i-study-tpf-induction-chemotherapy-followed 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/eortc-24051-unexpected-side-effects-phase-i-study-tpf-induction-chemotherapy-followed 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/eortc-24051-unexpected-side-effects-phase-i-study-tpf-induction-chemotherapy-followed 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/laryngeal-preservation-induction-chemotherapy-hypopharyngeal-squamous-cell-carcinoma-10-year 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/laryngeal-preservation-induction-chemotherapy-hypopharyngeal-squamous-cell-carcinoma-10-year 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/laryngeal-preservation-induction-chemotherapy-hypopharyngeal-squamous-cell-carcinoma-10-year 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/new-imaging-techniques-90y-microsphere-radioembolization 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/new-imaging-techniques-90y-microsphere-radioembolization 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/new-imaging-techniques-90y-microsphere-radioembolization 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/joint-model-dependence-between-clustered-times-tumour-progression-and-deaths-meta-analysis-0 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/joint-model-dependence-between-clustered-times-tumour-progression-and-deaths-meta-analysis-0 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/joint-model-dependence-between-clustered-times-tumour-progression-and-deaths-meta-analysis-0 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/examining-relationships-among-health-related-quality-life-indicators-cancer-patients-participating 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/examining-relationships-among-health-related-quality-life-indicators-cancer-patients-participating 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/examining-relationships-among-health-related-quality-life-indicators-cancer-patients-participating 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/zygomycosis-europe-analysis-230-cases-accrued-registry-european-confederation-medical-mycology-ecmm 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/zygomycosis-europe-analysis-230-cases-accrued-registry-european-confederation-medical-mycology-ecmm 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/zygomycosis-europe-analysis-230-cases-accrued-registry-european-confederation-medical-mycology-ecmm 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/moterhood-after-breast-cancer-searching-la-dolce-vita-expert-rev 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/moterhood-after-breast-cancer-searching-la-dolce-vita-expert-rev 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/moterhood-after-breast-cancer-searching-la-dolce-vita-expert-rev 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/external-quality-assurance-circulating-tumor-cell-enumeration-using-cellsearchr-system-feasibility 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/external-quality-assurance-circulating-tumor-cell-enumeration-using-cellsearchr-system-feasibility 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/external-quality-assurance-circulating-tumor-cell-enumeration-using-cellsearchr-system-feasibility 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/surgical-management-toxic-multinodular-goiter 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/surgical-management-toxic-multinodular-goiter 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/surgical-management-toxic-multinodular-goiter 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/prevention-et-traitement-des-infections-textbook-therapeutique-du-cancer-morere-jf-mornex-f 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prevention-et-traitement-des-infections-textbook-therapeutique-du-cancer-morere-jf-mornex-f 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prevention-et-traitement-des-infections-textbook-therapeutique-du-cancer-morere-jf-mornex-f 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/urgences-et-complications-iatrogenes-chez-le-patient-cancereux-textbook-therapeutique-du-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/urgences-et-complications-iatrogenes-chez-le-patient-cancereux-textbook-therapeutique-du-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/urgences-et-complications-iatrogenes-chez-le-patient-cancereux-textbook-therapeutique-du-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/nouvelle-classification-tnm-oncologie-thoracique-textbook-collection-oncologie-pratique-morere-jf 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/nouvelle-classification-tnm-oncologie-thoracique-textbook-collection-oncologie-pratique-morere-jf 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/nouvelle-classification-tnm-oncologie-thoracique-textbook-collection-oncologie-pratique-morere-jf 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/combined-role-lymphoscintigraphy-x-ray-computed-tomography-magnetic-resonance-imaging-and-positron 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/combined-role-lymphoscintigraphy-x-ray-computed-tomography-magnetic-resonance-imaging-and-positron 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/combined-role-lymphoscintigraphy-x-ray-computed-tomography-magnetic-resonance-imaging-and-positron 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/high-throughput-sequencing-reveals-novel-micrornas-retrovirus-induced-ovine-model-leukemia-textbook 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/high-throughput-sequencing-reveals-novel-micrornas-retrovirus-induced-ovine-model-leukemia-textbook 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/high-throughput-sequencing-reveals-novel-micrornas-retrovirus-induced-ovine-model-leukemia-textbook 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/methodologie-et-analyse-des-essais-cliniques-cours-de-chimiotherapie-antitumorale-et-traitement 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/methodologie-et-analyse-des-essais-cliniques-cours-de-chimiotherapie-antitumorale-et-traitement 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/methodologie-et-analyse-des-essais-cliniques-cours-de-chimiotherapie-antitumorale-et-traitement 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/facteurs-pronostiques-et-predictifs-de-la-reponse-un-traitement-invited-chapter-methodes 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/facteurs-pronostiques-et-predictifs-de-la-reponse-un-traitement-invited-chapter-methodes 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/facteurs-pronostiques-et-predictifs-de-la-reponse-un-traitement-invited-chapter-methodes 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/introduction-gene-expression-profiling-breast-cancer-breast-surgical-techniques-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/introduction-gene-expression-profiling-breast-cancer-breast-surgical-techniques-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/introduction-gene-expression-profiling-breast-cancer-breast-surgical-techniques-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/multiple-testing-treatment-effect-modifying-biomarkers-randomized-clinical-trial-survival-endpoint 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/multiple-testing-treatment-effect-modifying-biomarkers-randomized-clinical-trial-survival-endpoint 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/multiple-testing-treatment-effect-modifying-biomarkers-randomized-clinical-trial-survival-endpoint 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/supportive-care-patients-gynaecological-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/supportive-care-patients-gynaecological-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/supportive-care-patients-gynaecological-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/construction-and-validation-support-inventory-context-smoking-cessation-sisc-smoker-and-their 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/construction-and-validation-support-inventory-context-smoking-cessation-sisc-smoker-and-their 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/construction-and-validation-support-inventory-context-smoking-cessation-sisc-smoker-and-their 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tomographie-par-emission-de-positons-au-18f-fdg-et-reponse-anticancereuse-determination-de-la 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/tomographie-par-emission-de-positons-au-18f-fdg-et-reponse-anticancereuse-determination-de-la 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/tomographie-par-emission-de-positons-au-18f-fdg-et-reponse-anticancereuse-determination-de-la 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/research-ethics-committee-universidade-federal-de-santa-maria-brief-historical-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/research-ethics-committee-universidade-federal-de-santa-maria-brief-historical-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/research-ethics-committee-universidade-federal-de-santa-maria-brief-historical-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/envelhecimento-e-doenca-cronica-editorial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/envelhecimento-e-doenca-cronica-editorial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/envelhecimento-e-doenca-cronica-editorial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/comparison-manual-and-automatic-segmentation-methods-brain-structures-presence-space-occupying 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/comparison-manual-and-automatic-segmentation-methods-brain-structures-presence-space-occupying 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/comparison-manual-and-automatic-segmentation-methods-brain-structures-presence-space-occupying 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/new-development-hormone-receptor-positive-disease 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/new-development-hormone-receptor-positive-disease 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/new-development-hormone-receptor-positive-disease 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/outils-genomiques-pouvant-aider-au-choix-therapeutique-des-cancers-du-sein-analyse-cancer-du-sein 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/outils-genomiques-pouvant-aider-au-choix-therapeutique-des-cancers-du-sein-analyse-cancer-du-sein 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/outils-genomiques-pouvant-aider-au-choix-therapeutique-des-cancers-du-sein-analyse-cancer-du-sein 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/biomarker-studies-call-comprehensive-biomarker-study-registry 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/biomarker-studies-call-comprehensive-biomarker-study-registry 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/biomarker-studies-call-comprehensive-biomarker-study-registry 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/multidimensionality-microarrays-statistical-challenges-and-impossible-solutions 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/multidimensionality-microarrays-statistical-challenges-and-impossible-solutions 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/multidimensionality-microarrays-statistical-challenges-and-impossible-solutions 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/proposals-uniform-collection-biospecimens-neoadjuvant-breast-cancer-clinical-trials-timing-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/proposals-uniform-collection-biospecimens-neoadjuvant-breast-cancer-clinical-trials-timing-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/proposals-uniform-collection-biospecimens-neoadjuvant-breast-cancer-clinical-trials-timing-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/assessment-letrozole-and-tamoxifen-alone-and-sequence-postmenopausal-women-steroid-hormone-receptor 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/assessment-letrozole-and-tamoxifen-alone-and-sequence-postmenopausal-women-steroid-hormone-receptor 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/assessment-letrozole-and-tamoxifen-alone-and-sequence-postmenopausal-women-steroid-hormone-receptor 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/relevance-breast-cancer-hormone-receptors-and-other-factors-efficacy-adjuvant-tamoxifen-patient 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/relevance-breast-cancer-hormone-receptors-and-other-factors-efficacy-adjuvant-tamoxifen-patient 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/relevance-breast-cancer-hormone-receptors-and-other-factors-efficacy-adjuvant-tamoxifen-patient 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/effect-radiotherapy-after-breast-conserving-surgery-10-year-recurrence-and-15-year-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/effect-radiotherapy-after-breast-conserving-surgery-10-year-recurrence-and-15-year-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/effect-radiotherapy-after-breast-conserving-surgery-10-year-recurrence-and-15-year-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/mln8054-small-molecule-inhibitor-aurora-kinase-sensitizes-androgen-resistant-prostate-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/mln8054-small-molecule-inhibitor-aurora-kinase-sensitizes-androgen-resistant-prostate-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/mln8054-small-molecule-inhibitor-aurora-kinase-sensitizes-androgen-resistant-prostate-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/practical-use-genotype-helicodr-molecular-test-helicobacter-pylori-detection-and-susceptibility 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/practical-use-genotype-helicodr-molecular-test-helicobacter-pylori-detection-and-susceptibility 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/practical-use-genotype-helicodr-molecular-test-helicobacter-pylori-detection-and-susceptibility 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/leukemia-free-survival-surrogate-end-point-overall-survival-evaluation-maintenance-therapy-patients 2024-03-03T07:00:03+01:00 0.5